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SUMMARY 
 
Cybr (Cytohesin binder and regulator) is an adaptor protein involved in the assembly and 
recruitment of protein complexes associated with intracellular trafficking and signaling. Cybr has 
attracted attention as a potential key contributor to molecular mechanisms governing cells of the 
immune system due to its exclusive expression in cells of hematopoietic origin. Cybr interacts with 
members of the ADP ribosylation factor (ARF)-activating cytohesin family, mainly cytohesin-1, 
and it is involved in the cytohesin-1-mediated adhesion of LFA-1 to ICAM-1. Cybr expression is 
highly and rapidly responsive to, and regulated by, many cytokines and other soluble effectors of 
the immune system suggesting a potential functional role in the vesicle formation, endocytic 
trafficking, regulation of TCR signalling and regulation of dendritic cell (DC)/T cell interaction 
during the antigen presentation. To characterize the in vivo physiological role of this molecule, a 
Cybr-deficient mouse strain was created. Cybr deletion does not profoundly affect the development 
of the immune system, but Cybr-KO mice display a reduced or delayed capacity to respond to 
different stimuli and in stress conditions.  
This project aimed at investigating the biological function of Cybr in cell-mediated immune 
response to tumors induced by the retroviral complex constituted  by the Moloney murine sarcoma 
virus/Moloney murine leukemia virus (M-MSV/MuLV, hereafter indicated as M-MSV). 
Intramuscular injection of M-MSV in immunocompetent C57BL/6 (B6) mice causes sarcomas that 
spontaneously regress because of a strong immune reaction primarily mediated by cytotoxic T 
lymphocytes (CTL) specific for viral antigens. Conversely, Cybr-deficient mice injected with M-
MSV developed larger tumors than B6 mice, which additionally regressed with a slower kinetics. 
To disclose the biological bases of this behavior, M-MSV-injected Cybr-deficient and wild type 
mice were characterized for the lymphocyte phenotype and function in tumors, lymph nodes and 
spleens at the peak of tumor growth (day 11 to 15). We found a reduced number of CD4+ and CD8+ 
T cells, as well as of antigen-specific CTL, in the tumor infiltrating cells (TIL) of Cybr-deficient 
mice. However, this defect was recovered after a short temporal shift.  
Similarly, a three-day delay was also reported in the onset of lytic activity in Cybr-deficient respect 
to wild type CTLs. On the contrary, wild type or Cybr-deficient memory T cells from tumor 
regressor mice did not show any difference in terms of lytic activity. Overall, these data indicate 
that Cybr deficiency has a significant impact on the activation of naive T cells and expansion of 
primed T cells, but do not clarify whether Cybr mostly influence priming and/or cell adhesion or 
trafficking and migration of immune system cells. To address this issue, we transferred naive Cybr-
KO or wild type GFP T cells in tumor-bearing RAG2-/- γc-/- mice, that lack T, B and NK cells and 
6 
 
do not spontaneously regress M-MSV-induced tumors. Despite T cell transfer, tumors continued to 
growth indicating that transferred naive T cells were not able to mount a fully effective immune 
response in this setting. This was probably due to a suboptimal recruitment and priming phase in 
lymph nodes, that were found to be hypoplastic. To provide a mechanistic insight, reconstitution of 
nu/nu athymic B6 mice with T cell-depleted bone marrow from either wild type or Cybr-KO mice, 
followed by adoptive transfer of naive or memory T cells from Cybr-KO/GFP or B6/GFP animals, 
will provide the appropriate experimental set up to assess the role of Cybr in the APC or T cell 
compartments.   
Taken together, outlined results indicate that Cybr deficiency has a significant impact on antigen-
specific immune response, but further studies have to be performed to fully dissect the role played 
by this molecule in the priming phase and in the delayed onset of lytic activity. 
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RIASSUNTO 
 
Cybr (cytohesin binder and regulator) è una proteina adattatrice coinvolta nell’assemblaggio e nel 
reclutamento di complessi proteici associati con il trafficking intracellulare e la trasduzione del 
segnale. Grazie alla sua esclusiva espressione in cellule di origine ematopoietica, Cybr ha attirato 
l’attenzione come potenziale proteina chiave nei meccanismi molecolari che controllano le cellule 
del sistema immunitario. Cybr interagisce con i membri della famiglia delle citoesine attivanti gli 
ADP ribosylation factors (ARF), specialmente con citoesina-1, e regola l’adesione citoesina-1 
mediata di LFA-1 a ICAM-1. La sua espressione è rapidamente regolata da molte citochine e da 
altri effettori solubili del sistema immunitario. Alcuni ruoli funzionali proposti per questa molecola 
sono la partecipazione nella formazione delle vescicole, nel trafficking endocitico, nella regolazione 
del signaling del TCR e nell’interazione tra cellule dendritiche e cellule T durante la presentazione 
dell’antigene. Al fine di caratterizzare il ruolo fisiologico di questa molecola in vivo, è stato creato 
un ceppo di topi deficienti per Cybr. Questi topi, nonostante  un normale sviluppo del sistema 
immunitario, mostrano una ridotta o ritardata capacità di rispondere a diversi stimoli e in condizioni 
di stress.  
Questo progetto di ricerca si è prefisso di investigare la funzione biologica di Cybr nella risposta 
immunitaria cellulo-mediata nei confronti di tumori indotti dal complesso retrovirale costituito dai 
virus sarcomatogeno e leucemogeno murini di Moloney (M-MSV/MuLV, in seguito indicato come 
M-MSV). L’inoculo intramuscolare di M-MSV in topi C57BL/6 (B6) immunocompetenti causa lo 
sviluppo di sarcomi che regrediscono spontaneamente grazie ad una forte risposta immunitaria 
mediata principalmente da linfociti T citotossici (CTL) specifici per gli antigeni virali. Al contrario, 
topi Cybr-deficienti inoculati con M-MSV sviluppano tumori di dimensioni maggiori e che 
regrediscono più lentamente rispetto ai controlli. Per comprendere i motivi di questo diverso 
andamento, dopo l’inoculo del complesso retrovirale in topi Cybr-deficienti e wild type, sono stati 
caratterizzati a livello fenotipico e funzionale i linfociti presenti nei tumori, nei linfonodi drenanti e 
nelle milze al momento della massima crescita tumorale (giorni 11-15). Abbiamo riscontrato un 
ridotto numero di linfociti T CD4+ e CD8+ e di CTL antigene specifici nella popolazione infiltrante 
il tumore nei topi Cybr-deficienti. Tuttavia questa differenza si è ridotta alla fine del periodo 
analizzato.  
Inoltre, un ritardo simile è stato riportato nello sviluppo dell’attività litica nei CTL provenienti da 
topi Cybr-KO rispetto a topi wild type. Al contrario, linfociti T memoria wild type e Cybr-KO non 
hanno mostrato nessuna differenza in termini di attività litica. Complessivamente, questi dati 
indicano che la deficienza di Cybr ha un significativo impatto nell’attivazione delle cellule T naive 
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e nella loro espansione dopo il priming, ma non definiscono se questa proteina influenzi 
maggiormente la fase di priming e/o adesione cellulare o il trafficking e la migrazione delle cellule 
del sistema immunitario. Per chiarire questi aspetti, sono stati trasferiti linfociti T naive provenienti 
da topi Cybr-KO/GFP o B6/GFP in topi RAG2-/- γc-/- inoculati con il complesso retrovirale. Questi 
topi mancano di cellule T, B e NK e non regrediscono spontaneamente i tumori M-MSV indotti. 
Nonostante l’infusione di cellule T, i tumori hanno continuato a crescere, indicando che le cellule T 
naive non sono state in grado di montare una risposta immune pienamente efficace in questo 
modello, un aspetto probabilmente dovuto ad un reclutamento e priming sub ottimali nei linfonodi, 
che sono risultati ipoplastici. Al fine di rispondere a questi quesiti biologici, topi B6 nu/nu atimici 
ricostituiti con tessuto midollare depleto di linfociti T provenienti da topi wild type o Cybr-KO e 
successivamente infusi con linfociti T naive o memoria provenienti da topi Cybr-KO/GFP o 
B6/GFP, dovrebbero costituire un modello sperimentale ottimale per investigare il ruolo di Cybr sia 
nel comparto T che nel comparto APC.   
Nell’insieme, i risultati ottenuti indicano che la deficienza di Cybr ha un significativo impatto nella 
risposta immune antigene-specifica, ma studi addizionali devono essere condotti al fine di definire 
con maggior precisione il ruolo di Cybr nella fase di priming e nel ritardo dello sviluppo 
dell’attività litica. 
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INTRODUCTION 
1. The immune system: innate and adaptive immune responses  
The immune system evolved under selective pressure imposed by infectious microorganisms 
through various defense mechanisms that have the capacity to be triggered by infection and to 
protect the host organism by destroying the invading microbes and neutralizing their virulence 
factors. It is composed by two main arms, the innate and the adaptive immune response. The innate 
immune system is the first line of host defense against pathogens and is characterized by receptors 
with a fixed germline-encoded specificity, which recognizes a genetically-determined set of ligands. 
One key group of innate receptors is the pattern recognition receptor (PRR) superfamily which 
recognizes evolutionary-conserved pathogen-associate molecular patterns (PAMPs) [1]. Moreover, 
Toll like receptors play the major role in pathogen recognition and in inflammatory initiation of the 
immune responses [2]. Cells of the innate immune response include neutrophils, monocytes, 
macrophages and dendritic cells (DC), which react rapidly to control pathogen growth and promote 
inflammation [3]. However, remains unclear the molecular mechanism between the 
polymorphonuclear (PMN) cells and tumor cells. It is know that FcγR on PMN interacts with 
antibody-coated antigens on tumor cells, leading to the release of cytokines and chemokines which 
influence the recruitment and the activation of DC and macrophages in tumor site [4]. Macrophages 
can efficiently eliminate apoptotic tumor cells by phagocytosis. Furthermore, they express FcγR 
that, when is activate, stimulate cytotoxicity to tumor cells [5]. Nevertheless, the macrophages are 
the major contributors to a chronic inflammation that affords an immune suppression environment 
in the tumor milieu, that can benefit its growth [6]. The DC are professional antigen presenting cells 
(APC) and are the interface between the innate and adaptive immune response. When DCs 
encounter a pathogen, mature and process the antigen, increasing the Major Histocompatibility 
Complex (MHC) molecule expression, and migrate to the lymph nodes where they can prime the 
naive T cells [7].  
Normally the innate immune system responds with a rapid mechanism without recourse to the 
adaptive immunity; however, sometimes the innate system required this cross-talk with the adaptive 
immune response to deal with the infections [1]. Therefore, adaptive immunity is triggered in 
vertebrates when a pathogen evades the innate immune system and generates a threshold level of 
antigen [8]. An antigen (short for antibodygenerator), is defined as any substance (in particular, 
proteins and many polysaccharides) capable to bind to a specific antibody and elicit the adaptive 
immune response [9]. The parts of the antigen that interact with an antibody molecule or 
lymphocyte receptor (namely, BCR- B cell receptor, and TCR- T cell receptor, respectively) are 
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called epitopes. Most antigens contain a variety of epitopes and can stimulate the production of 
antibodies by B cells, specific T cell responses, or both. BCR and TCR possess variable regions 
created by a complex process of somatic gene segment rearrangement. This mechanism allows a 
small number of genes to generate a vast number of different antigen receptors, which are then 
uniquely expressed on each individual lymphocyte and also account for the varying and random 
specificities of immune cells. The variable-region receptors of the adaptive immune system respond 
to particular pathogen structures, with BCRs directly recognizing peptide sequences on pathogens, 
such as components of bacterial cell membranes, and TCRs recognizing peptide sequences only in 
the context of the MHC. As a result, B cells play a large role in the humoral immune response, 
whereas T cells are intimately involved in cell-mediated immune responses [10]. 
The efficiency of the adaptive immune response relies on the capacity of immune cells to 
distinguish between the own body cells from unwanted invaders. The adaptive response is thus 
triggered only after recognition of non-self antigens. This ability is acquired during maturation 
processes in the thymus by T cells or bone marrow by B cells. In these organs, immature 
lymphocytes undergo positive and negative selection phases. In particular, in the thymus, immature 
T lymphocytes, harboring misfolded TCR or TCR that is unable to bind with self MHC molecules, 
are committed to die by apoptosis. Whereas, lymphocytes that recognize MHC complexes with the 
right avidity are selected (positive selection). During negative selection, T cells that strongly 
interact with MHC coupled with endogenous peptides are committed to die [10]. 
Finally, only naive lymphocytes able to recognize exogenous peptides in the context of self 
MHC can exit the thymus and reach lymph nodes, spleen and damage tissues. In the lymph nodes 
and spleens, lymphocytes interact with and are activated by mature dendritic cells only if their 
antigen receptors bind with the peptide presented by the DCs and they receive co-stimulatory 
signals from the DCs. Hence, naive T lymphocytes first undergo an intense period of proliferation, 
termed clonal expansion and then differentiate into either several classes of effector T lymphocytes 
or memory T lymphocytes. In the lymph node, DCs display non-self antigens on their surface by 
coupling them to MHC molecules (also known in humans as Human Leukocyte Antigen –HLA [9]. 
Although some exception does exist (cross-presentation process and autophagy), exogenous 
antigens are usually displayed on MHC class II molecules, which activate CD4+ helper T cells 
while endogenous antigens (from viral or mutated proteins), are typically displayed on MHC class I 
molecules, and activate CD8+ cytotoxic T cells. As well as activating T cells, DCs are important 
inducers of peripheral tolerance to self antigens, that are captured by DCs in the periphery and 
presented to T cells in the lymph nodes. Presentation of self antigens under steady state pathogen-
free conditions induces tolerization through T cell apoptosis or anergy [7],[11],[12]. 
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2. T cells 
2.1 Helper T cells  
T cells contribute to immune defenses in two major ways, by directing and regulating the 
immune responses and by directly attacking infected or cancerous cells. CD4+ lymphocytes, as 
called also helper T cells, are all variously involved in the regulation of immune responses, through 
the action of cytokines that either stimulate or inhibit the function of other lymphocytes and APC 
and furthermore lead to co-stimulation or direct inhibition through cell-to-cell interactions. These 
cells can also display direct cytotoxic activity [13], but primarily they manage the immune response 
by directing other cells to kill infected and cancerous cells or clear pathogens. 
CD4+ T lymphocytes can be grouped into different subsets according to functional properties 
and cytokines secretion patterns. Originally, these cells were simply classified as Type 1 (Th1) and 
Type 2 (Th2) helper T cells. The differentiation of Th1 is primarily driven by interleukin-12 (IL-12) 
and interferon-γ (INF-γ). Th1 regulates delayed type hypersensitivity reactions, cell-mediated 
immunity to intracellular pathogens and tumor cells by producing high levels of IFN-γ, tumor 
necrosis factor-α (TNF-α), and IL-2. Conversely, Th2 cells are characterized by IL-4, IL-5, IL-10, 
and IL-13 production, operate in coordinating humoral immunity, eosinophilic inflammation, and 
are also involved in the control of helminthic infections. 
In the last few years, new distinct subsets of CD4+ T cells have been identified. A lineage 
distinct from Th1 and Th2 was recently described as Th17 cells, a CD4+ T cell subset that 
selectively produces the IL-17 cytokine, in addition to TNF-α, IL-6, IL-21, and IL-22. The 
autocrine production of IL-21, together with IL-1 and low doses of IL-12, were shown to 
antagonize the Th1 differentiation in favor of Th17. Moreover, IL-23, whose action is inhibited by 
IFN-γ and IL-4, is necessary for the maintenance of Th17 and IL-17 production. Th17 are supposed 
to coordinate tissue inflammation and autoimmunity and protect against extracellular bacteria and 
fungi [14],[15]. More recently, a population of CD4+ T cells secreting IL-22, but neither IL-17 nor 
IFN-γ, was isolated from human skin-homing memory T cells, and, therefore, identified as Th22 
[16],[17]. The differentiation of this subpopulation of helper T cells, that show a potential role in 
skin homeostasis and diseases [18], may be promoted by stimulation of naive T cells in the presence 
of IL-6 and TNF or by the presence of plasmacytoid dendritic cells [16],[19]. 
In addition to helper cells, CD4+ T lymphocytes also include a heterogeneous population of 
cells endowed with regulatory functions, namely regulatory T cells (Tregs). In particular, Tregs are 
of pivotal importance in the homeostatic control and suppression of immune responses, thus 
constituting an important mechanism in controlling the autoimmune diseases development. Tumor 
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Growth Factor-β (TGF-β)-induced, naturally occurring or peripherally-induced Tregs derive from 
the thymus and express high levels of CD25, glucocorticoid-induced TNF receptor, and the 
transcription factor forkhead box protein 3 (FoxP3). These cells mediate immune suppression 
through a cell-to-cell contact-dependent mechanism and, once activated, they are able to induce 
suppression in an antigen-independent fashion [20],[21]. 
 
2.2 CD8+ T lymphocytes and cytotoxicity 
Cytotoxic T lymphocytes (CTL) are a sub-group of T cells whose role is to monitor all the 
cells in  the body, and are ready to destroy any that is considered to be a threat to the integrity of the 
host; for example, CTLs kill virally infected cells, preventing them from being the source of more 
viral pathogen [22]. Moreover, CTLs are also thought to provide some degree of protection against 
spontaneous malignant tumors, by virtue of their ability to detect quantitative and qualitative 
antigenic differences in transformed cells. In this regard, transformation results in an altered protein 
repertoire that can be sensed by CD8+ T cells through binding of peptide-MHC class I complexes 
[23]. 
Naive CD8+ T cells are activated into effector cells when their TCR strongly interacts with a 
peptide-bound MHC class I molecule and concomitantly receive costimulatory and IL-2 mediated 
signaling. Once activated, CTL undergo a process called clonal expansion in which it gains 
functionality, and divides rapidly, to produce an army of effector cells, that display cytotoxic 
activity upon encounter of an infected or mutated target cell in an inflammatory milieu. CTLs may 
kill target cells by one of, at least, three distinct pathways, two of which involve direct cell–cell 
interactions between effector and target cells. The third is mediated by cytokines, such as IFN-γ and 
TNF-α, that differently impact on target cells (Fig. 1a). In particular, TNF-α engages its receptor on 
the target cell and triggers the caspase cascade, leading to target-cell apoptosis. IFN-γ, however, 
induces transcriptional activation of the MHC class I molecules and Fas in target cells, leading to 
enhanced presentation of endogenous peptides, and increases Fas-mediated target-cell lysis. 
Cytolytic activity, requiring direct cell–cell contact which results in apoptosis of target cells, can be 
mediated by two different mechanisms. In one case, the Fas ligand, expressed on the surface of 
CTLs, binds to the Fas receptor (Fas, CD95) on the target cell (Fig. 1b) and triggers apoptosis 
through the classical caspase cascade [24]. In the other case, the CTL releases perforin and 
granzymes into the intercellular space (Fig. 1c) which are highly cytotoxic, but CTLs have 
elaborated a mechanism to protect themselves and neighboring cells from being killed accidentally. 
Firstly, the majority of the cytotoxic proteins are pre-synthesized, and so ready to be used in killing 
upon encountering a target cell. The regulated secretory organelles, in which the lytic proteins are 
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stored, mobilize themselves to the cell surface and expose their content only upon contact with a 
target. CTLs use their lysosomes as regulated secretory organelles, which are often referred as 
secretory lysosomes [25]. Secondly, the secretory lysosomes do not exocytose their content 
randomly, but are mobilized to a defined point in the plasma membrane that is immediately 
opposite the target cell, termed secretory domain of the immunological synapse (see below). 
Thirdly, the secretory lysosomes release their content into a defined space, or “cleft,” that is formed 
between the otherwise tightly opposed CTL and the target-cell membranes, thus sparing innocent 
neighboring bystander cells. This organization therefore, concentrates the cytotoxic proteins for 
maximum impact and confines them to the environment of the target cell. The entry of the granular 
material in target cell causes cell death in a caspase-dependent or –independent manner [26].  
 
 
 
 
Figure 1. CTL-mediated cytotoxicity. (a) Indirect killing of target cells by release of tumor necrosis factor-
α and IFN-γ. (b) Induction of apoptosis in target cells via death receptor triggering. (c) Direct killing by 
release of granzyme B and perforin into the intercellular space between CTL and target cell. TNF, tumor 
necrosis factor; TNFR, tumor necrosis factor receptor; IFNR, IFN receptor; Fas-L, Fas ligand. Modified 
from [22]. 
 
Upon infection resolution, most of the effector cells die by apoptosis due to prolonged 
activation (AICD, activation-induced cell death) and cytokines starvation or undergo a state of 
functional exhaustion [27]. Only a few of these antigen-specific cells are retained as memory cells 
[8]. Upon a later encounter with the same antigen, the memory cells quickly differentiate into 
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effector cells, dramatically shortening the time required to mount an effective response and 
conferring thus a protective immunity to the host. 
Progressive T cells differentiation from naive to effector and memory T cells is characterized 
by particular phenotypic, functional and transcriptional attributes [28]. Naive T cells (TN cells) are 
conventionally defined by the co-expression of the RA isoform of the transmembrane phosphatase 
CD45, the lymph node homing molecules L-selectin (CD62L) and CCR7, and the co-stimulatory 
receptors CD27 and CD28 [29]. These phenotypic characteristics facilitate T cell to entry into sec-
ondary lymphoid organs to probe APCs for cognate antigen and to respond to activating signals that 
give rise to more differentiated memory and effector progeny [30]. Among CD45RO-expressing T 
cells, two major subsets of memory T lymphocytes are defined on the basis of CD62L and CCR7 
expression [31]. Similar to TN cells, CD62L and CCR7 expression is retained on central memory T 
(TCM) cells, whereas it is lost on more differentiated effector memory T (TEM) cells. Functionally, 
these phenotypic differences allow antigen-specific TCM and TEM cells to patrol the central 
lymphoid organs and the peripheral tissues, respectively [30],[31]. The co-stimulatory receptors 
CD27 and CD28 are also found in the majority of memory T cells; however, expression can be lost 
as cells become terminally differentiated by progressively acquiring inhibitory signaling molecules, 
such as killer cell lectin-like receptor subfamily G, member 1 (KLRG1) [32],[33] and through 
transition into senescence [32],[34]. In contrast to TN cells, memory T cells are capable to rapidly 
release of cytokines on restimulation [35]. Both subsets are capable to produce TNF-α, while TCM 
cells secrete IL-2 more efficiently. TEM cells have an increased capacity to IFN-γ release and 
cytotoxicity [32],[31]. All antigen-experienced T cells upregulate the common IL-2 and IL-15β 
receptor (IL-2Rβ) — conferring the ability to undergo homeostatic proliferation in response to 
IL-15  [36],[37] — and also display high amounts of CD95 [38], a receptor that provides either 
co-stimulatory or pro-apoptotic signals depending on the efficiency of CD95 signalling complex 
formation and on which particular intracellular signaling proteins are part of the complex31. 
Recently, CD95 and IL-2Rβ have been found to be expressed in a subset of phenotypically naive-
appearing T cells [39]. These cells were observed in viral and tumor-reactive T cell populations 
and, similar to conventional memory T cells, displayed a diluted content of TCR excision circles, 
possessed the ability to rapidly release cytokines on activation and proliferation in response to IL-15 
[39]. These cells, the least differentiated population of antigen-experienced T cells identified to 
date, were termed stem cell memory T (TSCM) cells by virtue of their enhanced capacity to self-
renew and their multipotent ability to generate all memory and effector T cell subsets [39]. 
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2.3 The immunological synapse  
An immunological synapse (or immune synapse) is the interface between an antigen-
presenting cell and a lymphocyte [40]. In the CTL–target cell junction, a cascade of activation 
signals causes rapid segregation of cell surface receptors into three concentric compartments, called 
the central, peripheral and distal supramolecular activation complex (SMAC) (Fig. 2) [41]. The 
peripheral SMAC (pSMAC) comprises Leucocyte Function Associated antigen 1 (LFA-1), 
clustered with the cytoskeletal protein talin on the CTL, and Intercellular Adhesion Molecule 
(ICAM) on the target cell. Within the pSMAC is the central SMAC, where TCR accumulates. This 
area is also enriched in TCR associated signaling proteins including TCRζ, Lck, ZAP-70 and PKCθ, 
CD2, CD4, CD8, CD28,  Lck, and Fyn, and was assumed to be the site of TCR signaling. Beside it, 
there is a secretion domain where lytic granules fuse to release their content. The centrioles of the 
centrosome dock beside the cSMAC, which acts as a focal point for minus end microtubule-
mediated delivery of lytic granules. Actin accumulation occurs in a distal SMAC (dSMAC) (Fig. 2) 
[42], [43]. 
 
 
Figure 2. Schematic representation of the mature Immunological Synapse . The IS is composed of three 
major regions: the cSMAC containing TCR and accessory molecules, the pSMAC containing adhesion 
molecules and the dSMAC containing large and heavily glycosylated trans-membrane proteins. Intracellular 
signaling components and cytoskeleton components segregate in parallel with surface molecules within the 
three major zones of the IS. Modified from [44]. 
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The central part in the immunological synapse is the TCR, a heterodimer molecule 
responsible for recognizing antigens bound to MHC molecules. The TCR is composed of two 
different protein chains that are expressed as a part of a complex with the invariant CD3 chain 
molecule. In 95% of T cells, this consists of an alpha (α) and beta (β) chain, whereas in 5% of T 
cells this consists of gamma and delta (γ/δ) chains. Each chain is composed of a Variable (V) region 
and a Constant (C) region. The Constant region anchors the TCR to the cell membrane and 
including a short cytoplasmic tail, while the extracellular Variable region binds to the antigen-MHC 
complex.  
The Variable domain of both the TCR α-chain and β-chain have four hypervariable (HV) 
or complementarity determining regions (CDRs), that contact the antigen-MHC complex. TCRs 
possess unique antigen specificity, determined by the structure of the antigen-binding site formed 
by the alpha and beta chains [8], which are generated by V(D)J recombination. The unique 
combination of these segments, which corresponds to the CDR3 region, accounts for the great 
diversity in specificity of the T cell receptor for processed antigen. 
The TCR associates with other molecules like CD3, which possess three distinct chains (γ, δ, 
and ε) in mammals and either a ζ2 (CD247) or a ζ/η complex. These accessory molecules 
have transmembrane regions that are vital to propagate the signal from the TCR into the cell; 
the cytoplasmic tail of the TCR is extremely short, making unlikely to participate in signaling. The 
CD3- and ζ-chains, together with the TCR, form the T cell receptor complex. The TCR signal is 
enhanced by simultaneous binding to the MHC molecules by specific co-receptors, namely CD4 
and CD8 molecules, which not only ensure the specificity of the TCR for an antigen, but also allow 
prolonged engagement between the APC and the T cell and recruit essential molecules (e.g., Lck) 
involved in the intracellular signaling of the activated T lymphocyte. 
When the TCR engages antigens/MHC, the T lymphocyte become activated through a series 
of biochemical events mediated by associated enzymes, co-receptors, specialized accessory 
molecules, and activated or released transcription factors. The most common mechanism for 
activation and regulation of molecules beneath the lipid bilayer, is via 
phosphorylation/dephosphorylation by protein kinases. T cells utilize the SRC family of kinases in 
transmembrane signaling largely to phosphorylate tyrosines that are part of immunoreceptor 
tyrosine-based activation motifs (ITAM) [45]. 
In particular, when a T cell receptor is activated by contact with a peptide-MHC complex, 
CD45 dephosphorylates and activates Fyn, which in turn phosphorylates the ITAMs on the CD3 
and ζ chains. This allows other kinases like ZAP-70 to bind on the ITAM near Lck, previously 
recruited and activated by CD4 or CD8. Lck phosphorylates ZAP-70, which in turn indirectly 
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activate PLC-γ, resulting in gene transcription in the nucleus [46]. This is accomplished through an 
adaptor protein such as LAT, which brings together the activate ZAP-70 and PLC-γ. The 
recruitment of proximal signaling kinases like ZAP-70 and adaptor proteins, initiates a downstream 
signaling cascade events including activation of Rho family GTPases, Ras/MAPK, PLC, and 
Ca2+ mobilization [47],[48],[49]. The actin cytoskeleton reorganizes, the Golgi and the microtubule-
organizing center (MTOC) reorient toward the target cell [50],[51]. Upon TCR ligation, cytolytic 
granules move via polarized microtubules to the region of the MTOC where they dock prior to 
release. The mechanisms regulating the docking fusion and the release process are not well 
understood. However, there is evidence to suggest important roles for the small GTPase Rab27A, 
and Munc13-4, a member of a family of proteins known for their roles in priming neuronal synaptic 
vesicles for fusion and release [52],[53]. In the CTL synapse, vesicle release appears to occur in a 
secretory domain distinct from the signaling domain containing the TCR complex [54],[55]. The 
close opposition and highly organized topography of the CTL synapse, allows the release of highly 
toxic components of secretory granules in a process that likely avoids damaging nearby cells. Tight 
control is critical since the contents of just a small number of granules are enough to elicit apoptosis 
in the target cell [54]. 
However, there are key differences between the synapse formed by active CD8+ CTLs and 
CD4+ T cells. A CD4+ T cell interaction with its target may last many hours, prolonging signaling 
cascades necessary for gene activation, proliferation, and differentiation, while a CTL might only 
require minutes to initiate an irreversible apoptosis cascade to its target [54]. The antigen/MHC I 
recognition complex is a potent inducer of CTL cytotoxic activity. Remarkably, as little as one 
TCR/MHC I interaction may be all that is necessary to elicit a cytolytic response [56]. 
 
3. Trafficking and cell adhesion 
 
3.1 Molecules involved and mechanisms 
Trafficking and cell adhesion are key properties of both innate and adaptive immune 
responses. To facilitate T cell interaction with antigen-presenting cells, leukocytes that circulate as 
non-adherent cells, can be recruited to a specific site of infection or inflammation [57]. Cytokines 
(i.e. IL-4 or IFN-γ) released at the site of infection, create a chemotactic gradient to recruit T cells 
and inflammatory stimuli, activate vascular endothelial cells to express adhesion molecules and 
chemokines that physically engage circulating leukocytes and promote their adhesion to these 
vessels. The process of recruitment first involves T cells rolling along the surface of vascular 
endothelial cells, followed by the arrest and, finally, transendothelial migration (diapedesis) of T 
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cells into tissue [58],[59],[60],[61]. The cell adhesion molecules (CAMs) involved in the initial 
steps of recruitment are E- and P-selectins, followed by L-selectin [62],[63]. The arrest process 
involves the tethering (adhesion) and spreading of T cells [64],[65]. Molecules that play a critical 
role in controlling this process are integrins, such as Very Late Antigen-4 (VLA-4), which is one of 
six identified β1 integrins, and LFA-1, a member of the β2 integrin family [66],[67]. The ligands for 
these integrins include VCAM-1 (Vascular Cell Adhesion Molecule-1) for VLA-4 and ICAM-1, -2, 
and -3 for LFA-1. In particular, LFA-1, a cell surface receptor found on leukocytes, is composed by 
αL- and β2-subunits, which are designated as CD11a, and CD18, respectively. The αL-subunit of 
LFA-1 contains an I- (inserted) domain that is essential for binding to ICAM-1. ICAM-1, a member 
of the immunoglobulin superfamily (IgSF), is a transmembrane glycoprotein that has five 
immunoglobulin-like domains (D1–D5); mutational studies have revealed that domain-1 (D1) 
contains residues that are crucial for binding to LFA-1 [68],[69]. ICAM-1 is found at the cell 
surface of endothelial and epithelial cells, leukocytes, dermal fibroblasts, melanocytes, and many 
carcinoma cell types; its expression is up-regulated by cytokines such as IFN-γ, IL-1, and TNF-α, 
leading to a selective recruitment of leukocytes in a variety of pathological states [70],[71]. 
The secure adhesion of T cells to epithelial or endothelial cells represents the demarcation 
point that allows T cells to complete extravasation into the surrounding tissue. When ICAM-1/LFA-
1 interact, the adhesion mediated by VLA-4 and -5 decreases, indicating that a hierarchy exists in 
which LFA-1 plays a predominant role over VLA-mediated T cell migration [72]. By inhibiting 
ICAM-1/LFA-1 interaction, T cells are prevented from firm adhesion to epithelial, endothelial, or 
APC cells and are thus prevented from taking part in the immune response. 
The ICAM-1/LFA-1 interaction plays also a critical role during the priming phase. Indeed, 
naive T cells require both an antigen-specific and a co-stimulatory signal (namely, Signal-1 and 
Signal-2, respectively) to be fully activated during the interaction with the APC [40]. This co-
stimulatory signal is provided by interactions of several different pairs of molecules at the interface 
between T cells and APC, including LFA-1 on T cells and ICAM-1 on the APC or B-7 (found on B 
cells) and CD28 (found on T cells). The TCR-MHC-antigen binding in the absence of the Signal-2, 
not only fails to activate the cell, but also leads to a state called anergy, in which the T cell becomes 
refractory to activation. A high density of TCR–MHC-antigen complexes cannot compensate for 
the lack of a co-stimulatory signal such as ICAM-1/LFA-1 interaction for CD4+ T cell 
activation [73]. Moreover, the source of this secondary signal can influence the type of response 
generated by T cells. For example, blocking CD28/B-7 inhibits IL-4 and IL-5 (Th2 cytokines) 
production, while blocking ICAM-1/LFA-1 leads to a significant increase in Th2 cytokines [74]. 
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Another study demonstrated that co-stimulation by ICAM-1/LFA-1 strongly inhibits IL-10 
production, which may favor the development of Th1 rather than Th2 cells [75]. 
3.2 Integrin regulation 
Integrins participate in T cell activation and effector functions by promoting T cell contact 
with APCs during antigen recognition and priming [76]. Moreover, they are important in the 
migration and retention of T cells in different microenvironments in the body. Naive T lymphocytes 
exhibit a high rate of motility that facilitates rapid movement into and through secondary lymphoid 
organs [77],[78], where they are continually exposed to integrin cognate binding partners. 
Consequently, integrin receptors expressed on unactivated T cells exhibit a low basal state of 
functional activity that does not promote strong adhesion between T cells and relevant counter-
receptors and extracellular matrix ligands. However, upon TCR ligation, the functional activity of 
integrins is rapidly enhanced following stimulation of the antigen-specific CD3/T cell receptor 
(TCR) complex; it results in robust increases in integrin-mediated adhesion of T cells to purified 
integrin ligands and to antigen-laden APCs [79],[80],[81] and reduced motility in vitro [82], and 
enhanced interaction with APCs in lymphoid organs during antigen stimulation in vivo [77],[78]. 
Thus, integrin activation provides a mechanism by which T cells can enhance their interactions with 
the extracellular environment in order to receive and integrate extracellular signals critical for 
optimal antigen-dependent T cell activation and differentiation [83]. In this so-called outside-in 
signaling, cytohesins have been implicated as possible signaling intermediates. Integrin activation 
initiated by TCR occurs within minutes following T cell stimulation and is one of the earliest 
detectable changes in the behavior of T cells following activation. Increased integrin-mediated 
adhesion following TCR stimulation does not require changes in levels of integrins on the T cell 
surface. Consequently, alterations in integrin function following TCR signaling involve either 
qualitative alterations in integrin conformation or enhanced clustering of integrins on the T cell 
surface. Changes in the redistribution of integrins in response to TCR signaling have been well 
documented, the most notable examples is the movement of the LFA-1 and a4b1 integrins to the 
periphery in the contact site between activated T cells and  APC [41],[84],[85]. However, changes 
in integrin conformation in the context of antigen stimulation of T cells, particularly in vivo, are 
incompletely understood. In the case of T cells, analysis of LFA-1 function using fluorescence 
photobleaching recovery and single-particle tracking has shown that LFA-1 mobility (regulated by 
cytoskeletal attachment) and conformation are clearly linked [86]. These experiments indicate that 
multiple conformations of LFA-1 exist on the T cell surface, each with a unique diffusion profile. 
On resting T cells, both inactive and active conformations of  LFA-1 are mobile, while intermediate 
conformations of  LFA-1 are tethered to the cytoskeleton and thus are immobile (Fig. 3). 
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Stimulation of T cells with the phorbol ester phorbol-12-myristate-13-acetate (PMA), which 
activates protein kinase (PK) C, releases cytoskeletal constraints on the intermediate LFA-1 
receptors, thereby promotes receptor–ligand interactions. In contrast, LFA-1 in the active 
conformation, becomes immobile following stimulation to stabilize adhesion, and this cytoskeletal 
attachment is further enhanced following ligand engagement. Thus, changes in the distribution of 
the LFA-1 various conformations between mobile and cytoskeleton-attached immobile pools 
provides a dynamic mechanism by which T cells can regulate their adhesive potential. The ability to 
rapidly modulate integrin function in response to external signals is common to many hematopoietic 
cells. In particular, the control of the activation status of LFA-1on DC may be a key mechanism by 
which these cells regulate their interaction with T cells [87]. 
Early during the T cells priming, a scanning process takes place, connecting the antigen-
presenting cell with the T cell for a limited time. [78],[88]. The initial contact between T cells and 
DCs is antigen independent, [89] and only if antigen recognition occurs, the interaction is 
productive, leading to a strengthening of the conjugate, synapse formation and finally activation of 
antigen-specific T cells. Otherwise, the interaction between T cell and DC is loose and transient 
[90],[77],[43]. In both cases the connection release between the two cell types is necessary to 
continue the process of immune response, either to allow the clonal expansion of activated T cell or 
to continue the scanning process. Although many molecules are known to build cell conjugates, the 
termination of them was not equally studied. Given the importance and the calculated incidence of 
DC–T cell contacts during the scanning process, which ranges between 500 and 5000 encounters 
per hour [78], it is well assumable that this process is actively regulated. For example, the scaffold 
protein Cybr is an emerging candidate regulator of LFA-1 activity in both dendritic and T cells [87]. 
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Figure 3. A hypothetical scenario of signaling events underlying contact formation of T cells and 
antigen-specific DCs. Notice the cycle between guanosine diphosphate (GDP)-bound inactive Rap1 and 
guanosine triphosphate-bound active Rap1. The induction of the active form is mediated through the Ca2+ 
and DAG-guanine exchange factor (CalDAG-GEF), whereas the GTPase activity of Rap1 is initiated by the 
Rap1-GTPase-activating protein (Rap1GAP). Modified from [91]. 
 
4. The scaffold protein Cybr 
4.1 Discovery of Cybr gene 
Cytohesin binder and regulator (Cybr) is a novel adaptor protein that participates in the 
assembly and recruitment of protein complexes associated with intracellular trafficking and 
signaling. Owing to its exclusive expression in cells of hematopoietic origin, Cybr is consider a 
potential key contributor to molecular mechanisms governing cells of the immune system [92]. The 
Cybr cDNA was originally cloned and sequenced by Dixon and Pohajdak group in the early 1990s 
from a subtractive hybridization of human natural killer (NK) cell-enriched transcripts minus those 
of a T helper cell line [93]. Of the several hundred clones obtained, 13 were new, previously 
undiscovered gene transcripts. In 1998 the cDNA sequence for this protein named cytohesin-
binding protein HE has been deposited in the Genbank with the accession number AF068836. It 
was similar to the sequence of a protein termed B3-1 with the L06633, submitted by Dixon and 
colleagues [93], which today corresponds to a slightly truncated Cybr cDNA. On the basis of its 
deduced amino acid sequence, B3-1 was classified as a non-secreted non-membrane-bound protein 
containing an unusually long leucine zipper, a putative nuclear targeting sequence, and a motif 
found in many oncogenes, transcription factors and interleukins. The full transcript was finally 
elucidated  based on genomic clones and the human genome sequencing project, and the 29 kb gene 
was ultimately assigned to the human Chromosome 2 band q11.2 and renamed PSCDBP (Pleckstrin 
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homology Sec7 and coiled coil domains binding protein) [94], also known as Cybr, CASP 
(cytohesin-associated scaffolding protein,[95]) and CYTIP (cytohesin interacting protein,[96]). The 
Cybr gene comprises eight exons giving a transcript with a 1077 bp open reading frame, and 
corresponds to a polypeptide of 359 amino acids. 
 
4.2 Expression profile, transcriptional activation and transcript properties  
The expression profile of Cybr in Unigene (NCBI) reported high expression in the lymph, 
lymph nodes, blood, bone marrow, spleen and thymus and was supported also by northern analysis 
of a panel of cell lines, such as showed in lymphoid cells (NK/T cell) stimulated with PHA/PMA 
(phytohemagglutinin/phorbol 12-myristate 13-acetate) and/or interleukin (IL)-2. In particular, Cybr 
mRNA was found to increase 2-fold in NK/T cells upon stimulation with IL-12 and 25% upon 
stimulation with PHA/PMA [93]. Cybr expression has also been found in the lymphoblastoid cell 
line 721, in the T helper cell line Jurkat (increased upon stimulation with PHA/PMA) and in CD14+ 
monocyte-derived dendritic cells. Moreover, Cybr mRNA levels were dramatically higher in mature 
DCs (20-fold increase) when compared to immature cells.  
Cybr expression is also highly regulated in T cells, and several microarray studies and 
northern analysis have shown that induction of Cybr expression is affected by the stage of 
development of T cells; more differentiated CD3+ thymocytes express reduced Cybr levels than the 
less differentiated CD3- cells. Microarray, northern analysis and real-time PCR studies have 
demonstrated that Cybr in T cells is at least double expressed in Th1 polarized conditions compared 
to Th2 [92]. Cybr was later found to be overexpressed in T cells (Jurkat) following T cell receptor 
engagement, and to have effects on T cell receptor-dependent downstream events, such as 
enhancement of nuclear factor of activated T cell (NFAT). This aspect confers a role for Cybr to 
participate in the TCR signalling by regulating Vav phosphorylation and enhancing JNK and p38 
MAPK upon CD3 crosslinking [97]. Cybr expression not only increases NFAT activity but also 
NFAT may act on the Cybr promotor, since the upstream region of the Cybr gene contains 
numerous potential binding sites for NFAT as well as for several lymphoid-specific transcription 
factors. This sets up a potential positive feedback loop between Cybr and NFAT transcription during 
T cell activation and proliferation. Cybr expression also enhances AP-1 activation, that leads to 
enhance AP-1 transcriptional activity and involves co-operation with NFAT·AP-1[97].   
Overall, Cybr is widely accepted as a hematopoietic cell-specific transcript and it appears to 
be differentially regulated and specifically controlled within this lineage. Expression is basally low 
in many of these cell types, but is highly and rapidly responsive to, and regulated by, many 
cytokines and other soluble effectors of the immune system. In T cells and DCs, Cybr expression is 
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readily inducible by specific stimulation of each respective cell type. This attribute is surely a clue 
to the nature of in vivo Cybr protein function. 
 
4.3 Protein interactions, intracellular localizations and functional activities 
Cybr is a 40 kDa adaptor protein, since it contains multiple protein-protein interaction 
domains and motifs (namely, an N-terminal PDZ domain or PSD-95/Dlg/ZO-1, an unusually long 
central coiled-coil motif or leucine zipper and a C-terminal PDZ-binding motif or PDZbm) that 
participate in the assembly of larger protein complexes (Fig. 4) [98]. The coiled-coil motif mediates 
the interactions with cytohesin-1 (B2-1), the first Cybr binding partner discovered. The cytohesins 
are a ubiquitous group of proteins that have been variously implicated in several biological roles, 
including intracellular trafficking and signaling, through ARF (ADP-ribosylation factor) activation, 
cytoskeletal rearrangement, endocytic trafficking and cell adhesion through β2 integrin signaling. 
The intracellular Cybr function is particularly influenced by the interaction with cytohesin-1 (Fig. 
4), described using a yeast two-hybrid system, and further confirmed by in vitro protein-binding 
assays and in vivo using transfection and immunoprecipitation experiments. These studies also 
showed that Cybr could interact with other members of the cytohesin/ARNO family of guanine-
nucleotide exchange factors (ARNO/cytohesin-2 and ARNO/GRP1/cytohesin-3), demonstrating 
that Cybr may act as an adaptor for all members of this family.  
Another Cybr binding partners is represented by sorting nexin 27 (SNX27), a molecule with 
an active role in the polarization during lymphocyte migration and tumor cell engagement. Cybr 
interacts with SNX27 through PDZ-PDZbm interaction, thus bringing together members of the 
cytohesin/ARNO family to SNX27, as demonstrated in vivo in lymphocytes with co-
immunoprecipitation studies. Moreover, the co-localization of Cybr and SNX27 in early endosomal 
compartments implicates a function of this molecules in endocytic trafficking and/or signaling [99] 
(Fig.5). Finally, it is also possible that other proteins interact with the respective coiled-coil motif 
and the PDZbm, as these motifs can be promiscuous and interact with several distinct proteins. 
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Figure 4. Domain and motif architecture in the Cybr interactome. Protein domain distributions of Cybr, 
the cytohesin/ARNO family and SNX27. All four members (cytohesin-1, ARNO, ARNO-3 and cytohesin-4) 
of the mammalian family are identical in domain distribution. SNX27 exists as two isoforms with modified 
C termini. GRP1-associated scaffolding protein (GRASP), with a domain composition the same as CASP, 
may also play a role in potential redundant pathways. Domains: PDZ: PSD-95/Dlg/ZO-1; CC: coiled-coil; 
PH: pleckstrin homology; PX: phox homology; Sec7: guanine-nucleotide-exchange factor (GEF) activity 
with similarity to S. Cerevisiae SEC7 protein; RA: Ras-associated; B41: component of FERM. Modified 
from [98]. 
 
With regard to the intracellular localization, in the first experiments with transfected COS-1 
cells, full-length Cybr construct showed a perinuclear localization, but failed to display co-
localization with Golgi or endoplasmatic reticulum related proteins or markers. Moreover, Cybr was 
shown to be recruited by cytohesin-1 to separate subcellular locations, including the cytoplasm and 
membrane, dependent upon cytohesin-1 related signals [95]. 
Cybr localization, investigated in Jurkat cells, demonstrated that Cybr shows a cytoplasmatic 
and vesicular localization , and also it’s associated with the cortex with a cytoplasmatic domain 
directly below to the plasma membrane (Fig. 5). In cells co-expressing cytohesin-1 and Cybr, Cybr 
acts on, and sequester, cytohesin-1 from the membrane/cortex to the cytoplasm. The detachment of 
the Cybr-cytohesin-1 complex from the plasma membrane in turn induces the inhibition of the 
cytohesin-1-mediated adhesion of LFA-1 to ICAM-1 [96]. The relationship between the 
cytohesin/ARNO family and Cybr is found to be dynamic and differentially regulated. Indeed, 
while certain stimuli appear to cause cytohesin-1 recruitment of Cybr to the membrane (Epidermal 
Growth Factor-EGF and cell adhesion-associated events), others (PMA) induce Cybr to recruit 
cytohesin-1 away from the membrane/cortex to the cytoplasm. The regulation likely relies on both 
intracellular signaling and the particular cytohesin family member, as well as further protein 
components (such as Cybr-PDZ-binding partners, ARFs, and others), is associated with the 
particular complex implicated. 
In DCs, Cybr is localized in the cytoplasm in a very diffuse distribution. It was observed that 
normal immature DCs (characterized by low endogenous Cybr expression) adhere more effectively 
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than mature DCs (characterized by high endogenous Cybr expression), but Cybr silencing, using 
small interfering RNA, enhanced the adherence of mature DCs to fibronectin, indicating a role for 
Cybr in reducing DC adherence. Moreover, Cybr accumulates at the contact zone between dendritic 
cells and T cells when co-cultured [100]. Cybr silencing in dendritic cells inhibited their ability to 
efficiently detach from T cells during in vitro T-cell priming assays. In this way DCs keep longer 
contacts with T-cells and the stimulatory capacity for antigen-specific CD8+ T cells is diminished, 
indicating a possible role of Cybr in the de-attachment of T cells from dendritic cells  [100] (Fig. 5). 
 
 
Figure 5. A model implicating Cybr/CASP in putative novel polarized hematopoietic endosomal 
sorting events. A Cybr/CASP-mediated link between members of the cytohesin/ARNO family and SNX27 
gives this novel complex a dynamic affinity for phosphoinisitides enriched both at the plasma membrane 
(through the PH domain of cytohesins) and endosomal compartment (through the PX domain of SNX27). 
Likely, dependent on the cytohesin/ARNO implicated, vesicle initiation may take place on either membrane 
(for example with cytohesin at the plasma membrane or with ARNO at endosomal compartments). While 
shown from the T cell side, this complex may well support a parallel mechanism on the APC (antigen-
presenting cell) side. SE: sorting endosome; TGN: trans Golgi network; PI: phosphoinositol. Modified from 
[98]. 
Altogether, Cybr’s localization has emerged as dynamic and varied. Endogenous Cybr 
localization has been shown to be both endosomal and cytoplasmatic, depending on the cell-type 
examined. Cybr can translocate to and from the plasma membrane and/or cell cortex upon 
stimulation in a variety of contexts (for example EGF, PMA, cell adhesion, immune synapse 
formation) (Fig. 5). This localization pattern suggested functional roles of Cybr in ARF vesicle 
formation [101], endocytic trafficking and/or signaling [99], regulation of TCR signaling [97] and 
regulation of dendritic cell-T cell interaction times during the screening process for antigen-specific 
T cells [100]. In particular, the Cybr translocation in DCs to the immunological synapse is critical 
for efficient cell-cell interaction and detachment, allowing DCs to rapidly contact and subsequently 
leave T and B cells in their search for a T or B cell receptor corresponding to the presented antigen. 
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A reduction in the efficiency of these interactions, leading to longer and less cell-cell interactions in 
each case, would cumulatively promote a delayed and reduced migration of immune cells to 
appropriate tissue sites [102]. Indeed, reduced Cybr expression in DCs, leads to a longer 
interactions due to a reduced detachment during presentation to lymphocytes, and in vivo setting, 
this would wreak havoc on the process of screening naive lymphocytes to an efficient activation and 
proliferation [100],[102] (Fig. 6). 
 
 
Figure 6. A model depicting the role of Cybr expression in antigen presentation by dendritic cells. A) 
In normal conditions, antigen presentation at the lymph node involves interactions between DCs and T cells 
which include engagement, presentation and disengagement, followed by proliferation and migration of 
activated T cells. B) In the absence of Cybr, active disengagement is impeded, resulting in a bottleneck effect 
where ultimately fewer T cells are being primed, activated and exiting the lymph node and blood stream, as 
evidenced in several distinct studies [103],[104],[96] examining Cybr knockouts from both the T cell and DC 
side. Modified from [98]. 
4.4 Functional characterization in the context of immunity: insights from Cybr-knockout 
mouse models   
For in vivo characterization of Cybr, two Cybr-deficient mice were created, one by replacing 
parts of exon 2 and exon 3 by enhanced EGFP-encoding sequence [103], the other by the removal 
of exon 1 using the cre-lox system [104]. In both mouse models, the lack of Cybr only marginally 
affects the development of the immune system. A minor developmental of Cybr-deficient 
hematopoietic stem cells relative to wild-type cells in a bone marrow competitive repopulation 
model, was interpreted as not substantial, thus the role of Cybr was rated as nonessential, possibly 
due to functional redundancy with other proteins [103].  
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However, Cybr-deficient mice older than 6 months display fewer circulating white blood cells 
and lymphocytes in the inguinal lymph nodes [104]. With regard to functional activity, leukocytes 
trafficking was only impaired in stress conditions, namely Th1-polarized milieu. In an aseptic 
peritonitis model, Cybr-KO mice showed a significantly lower number of peritoneal inflammatory 
cells than wild type controls and only a limited reduction in the number of circulating WBC, due to 
the fact that neutrophils fail to efficiently exit the bloodstream. Moreover, the CD8-mediated 
immune response to Moloney murine sarcoma virus (M-MSV) is significantly delayed, in 
accordance with the impaired trafficking capacity of lymphocytes [104], and the finding that Cybr-
silenced human dendritic cells show a reduced stimulatory capacity for antigen-specific CD8 
positive T-cells [100].  
Contrasting results were obtained by Heib and colleagues [105] in a contact hypersensitivity 
model in Cybr-KO mice. Indeed, in deep contrast with human DC, they found that murine Cybr-KO 
dendritic cells display a greater ability to activate T cells [105]. Differences in the mouse model 
used and technical procedures can account for this discrepancy, but also a different Cybr expression 
between humans and mice has to be considered. Indeed, real-time PCR has shown that normal Cybr 
expression in mice is markedly lower than in humans, particularly in the thymus (~ 7-fold) and 
lymph node (~ 20-fold) [103]. 
Overall these observations point to a role for Cybr in a number of critical aspects of the 
immune response. Indeed, Cybr deficiency may affect lymphocyte interaction with vascular 
endothelial cells during rolling and extravasation in homing to tumor and infection sites and/or 
lymphoid organs, efficient migration and presentation of antigen by DCs to lymphocytes, and 
cytotoxic T lymphocytes interaction with cells targeted for destruction. Despite the fact that, due to 
the presence of redundant proteins, Cybr may not be essential in immunity under normal conditions, 
but it turn out to be a streamlined protein that greatly ameliorates the efficiency of the immune 
system under circumstances of significant stress.  
 
5. Tumor immunity and tumor antigens 
5.1 Cancer immunoediting: from immunosurveillance to immunoescape 
Cancer immunology is the study of interactions between the immune system and cancer cells. 
Progresses in the knowledge of the cell-mediated immune response function and of the tumor’s 
biology disclosed that a competent immune system has a key role in the prevention and treatment of 
cancer. The immune system has the ability to recognize antigens continuously generated by genetic 
and epigenetic events in the tumor [106],[107] and carry out humoral and cell-mediated responses 
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directed against tumor cells, potentially inhibiting the tumor development. The discovery of over 
1000 human tumor antigens and clinical evidences supported the fundamental concept of cancer 
immunosurveillance, developed first in 1957 by Burnet and Thomas. They proposed the theory 
that lymphocytes act as sentinels in recognizing and eliminating continuously arising, nascent 
transformed cells. Cancer immunosurveillance appears to be an important host protection process 
that inhibits carcinogenesis and maintains regular cellular homeostasis [106]. Important proofs 
came from studies conducted on immunodeficient mice and in particular in mice lacking B and T 
lymphocytes and STAT-1 (the transcription factor that mediates the IFN-γ-signaling) in which it 
was demonstrated a higher incidence of adenomas and adenocarcinomas compared to 
immunocompetent control mice. In human malignant tumors, the presence of leukocytes with 
specific properties of inhibiting the establishment and growth of tumor cells, was known since the 
1970 [108],[109]. Moreover, recent observations indicate that the infiltration of tumor by T cells is 
an important predictive marker of survival in several cancer types (e.g. ovarian and colorectal 
cancer) [110], [111]. 
During the tumor growth, continuous interactions between tumor cells and immune system 
take place at tumor site and at tumor draining-lymph node. In the initial phases of tumor 
development, even few antigenic differences between normal and mutated cells and the disruption 
of tissue homeostasis could activate local innate immune responses, mediated by macrophages, 
natural killer T cells (NKT) and natural killer cells (NK) [112]. Local inflammation recruits 
dendritic cells and promotes their maturation and migration to lymph nodes, where they become 
able to activate B and T cells, the effectors cells of the specific anti-tumor immune response. In 
tumors there is a synergy between the innate and adaptive immune response that maintain the 
malignant growth under control in a dynamic equilibrium. However, under the immunological 
pressure, some tumors could acquire mechanisms to evade or suppress the immune attack, thus 
surviving in the immunocompetent host [113].The tumor evolution in immunocompetent hosts is 
therefore associated with the selection of scarcely immunogenic cells and/or cells which are able to 
escape the immune-mediated effector mechanisms that could allow the tumor reject, as proposed by 
Dunn, Old and Schreiber [114],[115],[116] in the concept of immunoediting. The tumor 
immunoescape include alterations of immune effector mechanisms and/or acquisition by tumor 
cells of the resistance against the immune response. There are different mechanisms of tumor 
immune escape, for example the loss of components of the processing and presentation of antigen 
system, such as large multifunctional protease (LMP) and transporter associated with antigen 
processing (Tap), the downregulation of expression of MHC and co-stimulatory molecules as well 
as tumor antigens, especially the most immunogenic [117]. Furthermore, tumor cells could acquire 
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a resistance to CTL lysis [118], and the capacity to produce cytokines that inhibit T-cell responses, 
such as TGF-β or IL-10 [119], or could induce the apoptosis of T lymphocytes [120]. Tumor 
microenvironment, moreover, could supply signals that block the development of the innate 
immune response and consequently the inflammatory reaction [121]. In addition, tolerance or 
suppression of T lymphocytes can be induced by recruitment of myeloid-derived suppressors cells 
(MDSC) or other suppressors cells as NKT or T regulatory cells [122],[21]. 
 
5.2 Tumor antigens 
Tumor antigens are produced in tumor cells, and they can trigger an immune response in 
the host. The first proof of the presence of immunogenic molecules on tumor cells was 
demonstrated in chemical tumorigenesis studies, in which sarcomas methylcholanthrene-induced 
and then surgically removed, were rejected when transplanted in original hosts, while caused death 
in syngeneic previously untreated mice. Further studies revealed that the tumor rejection was related 
to the recognition of molecules present in the surface of transformed cells, called tumor antigens, by 
the host immune system. Tumor antigens were broadly classified into two categories based on their 
pattern of expression: Tumor-Specific Antigens (TSA), which are present only in tumor cells and 
not in normal cells and Tumor-Associated Antigens (TAA), which derive from not mutated 
proteins, are specific for particular cell lineages and are present in tumor cells but also in normal 
cells, even if at lower levels [117],[123]. 
Three classes of TAA can be distinguished: 
• Oncofetal antigens. These proteins are normally expressed in the early stages of embryonic 
development and disappear when the immune system is fully developed in adult tissues. α-
fetoprotein (AFP) and carcinoembryonic antigen (CEA) are well characterized oncofetal 
antigens. AFP is a α-globulin that is normally produced in the yolk sac and liver during fetal 
development, and successively is replaced by albumin. A relevant increase of AFP levels 
can be a symptom of a tumor mass presence in the liver or in germinal cells [124]. CEA is a 
membrane protein that belongs to Ig family, principally expressed in the gut, pancreas and 
liver during the first six months of gestation. The increase of CEA concentration is associate 
with colon tumors. The oncofetal antigens are not immunogenic, but they can be used for 
diagnosis and to monitor  an anti-tumor therapy and prognosis [125]. 
• Cancer/Testis antigens. Cancer/testis (CT) antigens are a category of tumor antigens with 
normal expression restricted to male germ cells in the testis but not in adult somatic tissues. 
In malignancy, this gene regulation is disrupted, resulting in CT antigen expression in a 
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proportion of tumors of various types [126]. Characteristics commonly shared by CT 
antigens, aside from the highly tissue-restricted expression profile, include existence as 
multigene families (namely MAGE, BAGE, GAGE, RAGE, NY-ESO-1), frequent mapping 
to chromosome X, heterogeneous protein expression in cancer, likely correlation with tumor 
progression, induction of expression by hypomethylation and/or histone acetylation, and 
immunogenicity in cancer patients [127]. 
• Tissue-specific or differentiation antigens. These antigens are encoded by genes expressed 
in tissue-specific manner which, in particular differentiation stages of cell cycle or tissue 
development, and can induce a T cell response. Among these antigens, melanocyte 
differentiation antigens (gp100 protein, MART-1/MELAN-A and tyrosinase) are important, 
as they were first identified in melanoma, but also in normal melanocytes [128]. Other 
examples are components of clusters of differentiation (CD) on lymphocytes, such as CD10 
or CALLA (Common Acute Lymphoblastic Leukemia Antigen), a molecule expressed on 
normal pre-B lymphocytes and on mature neoplastic B lymphocytes [129], and the Prostate-
Specific Antigen (PSA), a serine protease synthesized in epithelial cells of prostatic and 
vesical cancer, thus used as humoral marker for prostatic carcinoma [130]. 
• Altered cell surface glycolipidic and glycoproteic antigens. This class of antigens 
includes gangliosydes, mucins, glycolipids and glycoproteins expressed at unusually high 
levels on cell surface of several tumors. It is presumed that their presence can promote the 
invasion of surrounding tissues and the metastatic process. They can be used as anti-tumor 
vaccines for their ability to stimulate the production of IgM and IgG against tumor cells. 
The group of Tumor Specific Antigens comprises: 
• Antigens encoded by mutated oncogenes and tumor suppressor genes. Two groups of 
genes are included in this category: proto-oncogenes, which normally are silent and when 
activated or overexpressed become oncogenes and tumor suppressor genes involved in the 
regulation of cell cycle, which inactivation determines the production of mutated or the 
absence of proteins. Mutations of oncogenes  are recurrent, for example the p53 protein that 
if mutated is recognized by specific CTLs [131]. However, also  the native form of p53, as 
the protein encoded by Her2/Neu oncogene, is able to generate a specific CTL response, if 
produced in large amounts compared to normal levels [132]. 
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• Oncogenic viruses encoded antigens. Both DNA and RNA viruses can be involved in 
tumors development, in animal models and humans [133]. Several viruses own in their 
genome well-known oncogenes inducing therefore tumors and are defined as “acutely 
transforming viruses”, for example the Rous sarcoma virus and the Kirsten murine sarcoma 
virus. On the contrary, other viruses do not contain oncogenes in their genome, but are also 
able to induce tumors several months or years after the infection and are known as 
“chronically transforming viruses”. They can induce tumors not only by insertional 
mutagenesis, but also by expressing proteins that interfere with the activity of cellular genes 
and proteins involved in the growth, the differentiation or the transcription in normal cells. 
Examples of human oncogenic virus are represented by EBV (Epstein-Barr Virus), HTLV-1 
(Human T-lymphotropic type I Virus), HPV (Human Papilloma Virus), HBV (Hepatitis B 
Virus), HCV (Hepatitis C Virus) and KSHV (Kaposi’s Sarcoma Herpes Virus).  
Among murine tumor viruses, we focused our attention on the Moloney murine sarcoma 
virus/Moloney murine leukemia virus retroviral complex (M-MSV/MuLV), described in 
depth in the next Section, as a model in which characterize antigen-specific T cell responses. 
Indeed, from an immunological and immunotherapeutical point of view, viral tumor 
antigens represent a privileged group of antigens; indeed, due to their non-self origin, they 
are potentially able to induce even strong immune responses without the need to break 
tolerance. 
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6. Experimental model: the M-MSV/M-MuLV retroviral complex  
Moloney murine sarcoma virus (M-MSV) is an acutely transforming type C murine 
retrovirus, containing the oncogene mos in its genome. Mos encodes for a kinase protein that is 
responsible for the transformed phenotype. The oncogene insertion in the viral genome determined 
the deletion of envelope-encoding sequences; therefore, M-MSV is replication-defective and needs 
the helper activity of the chronic transforming Moloney murine leukemia virus (M-MuLV). 
Consequently, M-MSV particles as well as the virus-infected cells have the antigenic specificities 
associated to the helper virus M-MuLV. M-MuLV genome is constituted by gag, pol and env genes, 
by the LTR sequences and the encapsidation sequence E; the gag, pol, and env genes encode for the 
viral core proteins, for the reverse transcriptase enzyme and for the viral envelope, respectively 
(Fig. 7). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Experimental model of the viral oncogenesis. Intramuscular injection of the M-MSV/M-MuLV 
retroviral complex in immunocompetent C57BL/6 (B6) mice causes sarcomas to develop at the inoculation 
site, followed by subsequent spontaneous tumor regression.  
 
The gag gene contains the information for two principal precursors, the 65 kDa (Pr65gag) 
protein that is phosphorylated and cut in smaller proteins respectively of 15, 12, 30 and 10 kDa 
M-MSV/M-MuLV 
retroviral complex 
Tumor size 
Days after M-MSV 
injection 
33 
 
(p15, p12, p30 and p10), which constitute the viral capside proteins, and the 80 kDa (gPr80gag) 
protein that contains a N-terminal additional portion and is glycosylated starting from a 75 kDa 
precursor (Fig. 8). gPr80gag has no function for the replication of M-MuLV in vitro, but it is 
necessary for the efficient diffusion of viral infection and for the pathogenesis in vivo. The 
translation of this second precursor does not begin from the ATG of Pr65gag (located at base 621 
of the viral genoma), but from the upstream CTG, so determining the translation of an additional 
region in respect to the N-terminal of the protein [134]. 
 
 
 
Figure 8: Synthesis and post-translational modifications of the Gag polyproteins in the leukemia 
murine viruses (MLV). The scheme represents the metabolic pathways of glycosylated and non 
glycosylated MLV Gag polyproteins. The aminoacidic sequences of the two forms are identical, except for 
the N-terminal region, showed in grey. The localization of the glycosydic groups is indicated by the 
branched structures. Moreover, the phosphorylation and the proteolysis of the 65 kDa precursor are 
represented. The proteolysis produces the internal structural proteins of the mature virion. The numbers 
indicate the protein molecular weight expressed in kDa (pp12 = phosphoprotein of 12 kDa). 
 
The env gene encodes for a 80 kDa (gPr80env) precursor, that is glycosylated and cut in two 
proteins: gp70env that is involved in the entry of the virus in the cell, and p15env, the most 
hydrophobic protein of the viral particle that can be found associated to the virion and infected cell 
membrane. 
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Intramuscular injection of the M-MSV/M-MuLV retroviral complex in immunocompetent 
C57BL/6 (B6) mice, not older than 10-12 weeks, causes sarcomas to develop at the inoculation 
site after a short period of latency. Sarcomas reach the maximal growth about 10-12 days after the 
injection; subsequently, tumors regress spontaneously until they completely disappear [135]. 
Studies previously conducted in our laboratory demonstrated that this spontaneous regression is 
due to the induction of a strong virus-specific immune reaction, primarily mediated by CTLs 
specific for viral antigens. The T population integrity was demonstrated to be crucial in 
contrasting the M-MSV tumors development, and in operating their regression [136]. 
Using different approaches, two works led to the definition of two M-MuLV specific 
antigenic epitopes, one from gPr80gag and the other one by gp70env. The first one, namely Gag85-93 
(CCLCLTVFL) presented in the context of H-2Db allele, was identified as the immunodominant 
epitope by Chen and colleagues [137]. They studied the response generated by the immunization of 
B6 mice with FBL-3 cell line, a murine leukemia originally induced by the Friend leukemia virus. 
The Friend leukemia virus and the Moloney virus belong to the same group and share an elevated 
Gag sequence homology. The second peptide was described by Sijts e colleagues [138]. It is an 
optameric epitope, situated in position 189-196 of the gp70env aminoacidic sequence (SSWDFITV) 
and is presented in association with the H-2Kb allele.  
Previous experiments carried out in our laboratory confirmed the immunodominance of 
Gag85-93 peptide in terms of frequency of Gag-specific-pCTL in mice that regressed a M-MSV/M-
MuLV induced sarcoma, as assessed by limiting dilution analysis (LDA) technique. The majority of 
the tumor-specific CTL response is therefore directed against this epitope while the pCTL 
frequency that recognize Env189-196 is conversely much lower (8%) in regressors mice [139]. 
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AIM OF THE PROJECT 
Cybr is a scaffold protein mainly expressed in the hematopoietic cells and involved in the assembly 
and recruitment of protein complexes associated with intracellular trafficking and signaling. These 
characteristics place Cybr in a crucial position to control cell adhesion, cell-cell interactions, and 
migration of cells of the immune system. 
This research project aimed at characterizing in vivo the physiological role of Cybr in the cell-
mediated immune response in a mouse model of sarcoma induced by the M-MSV retroviral 
complex. By taking advantage of a Cybr-deficient mouse strain, we focused our attention 
principally on T cells dynamics in tumors, spleens and lymph nodes. In particular, we compared the 
phenotype, the antigen specificity and the lytic activity of Cybr-KO and wild type T cells at the 
peak of tumor growth and after its spontaneous regression. Furthermore, we investigated the 
priming phase and the tumor homing capacity of naive Cybr-deficient/GFP T cells adoptively 
transferred in M-MSV tumor-bearing Rag2-/- γc-/- mice. 
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MATERIALS AND METHODS 
 
1. Mice 
All mouse strains were housed in our Specific Pathogen Free (SPF) animal facility. Procedures 
involving animals and their care were in conformity with institutional guidelines that comply with 
national and international laws and policies (D.L. 116/92 and subsequent implementing circulars). 
The experimental protocols were approved by the local Ethical Committee of Padua University 
(CEASA). Mouse strains used for this study are reported as follows: 
 
C57BL/6 (B6) mice. 6–8-week-old female C57BL/6 (B6) mice (H-2b) were purchased from Charles 
River Laboratories (Calco, Como, Italy). 
 
C57BL/6-Tg (UBC-GFP) mice. These transgenic mice were purchased from Charles River 
Laboratories and are hereafter indicated as as B6/GFP mice. They express the enhanced Green 
Fluorescent Protein (eGFP) under the transcriptional control of the human ubiquitin C promoter. 
Mice homozygous for the transgene are viable, fertile, normal in size and do not display any gross 
physical or behavioral abnormalities. Some hematopoietic cell types display distinct expression 
levels of GFP, allowing identification of different cell types by cytometry analysis. GFP expression 
is uniform within a cell type lineage and remains constant throughout development. T cells have a 
2-fold higher GFP expression than CD19+B220+ B cells or peripheral blood cells.  
 
Cybr-deficient mice. This strain was generated and kindly provided by Coppola and colleagues 
[104]. The Cybr-specific targeting vector was obtained by DNA recombinant technology. Briefly, 
an 8.8-kb DNA fragment containing Cybr exon 1 (EX1) was retrieved from BAC 265C23 (ResGen; 
Invitrogen Corp., Huntsville; AL) and inserted into the targeting vector. Subsequently, by 
recombination in the DY380 bacterial strain, a loxP site was introduced 83 bp upstream of EX1. 
Finally, a cassette containing the neo resistance gene flanked by both loxP and Frt sites was placed 
63 bp downstream of EX1. Cybr-mutant mice were generated by a standard gene-targeting 
approach using the CJ7 embryonic stem cell line, as previously described. Removal of EX1 was 
accomplished by crossing the offspring of chimeras with the targeted allele to a Cre deleter strain. 
Resulting mice were negatively selected for the presence of Cre and backcrossed with B6 mice for 
nine generation in the original animal facility, and up to generation 22 after being imported in our 
facility, before being used for experiments.  
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Cybr-deficient/GFP mice. The Cybr-deficient/GFP mice were obtained by crossing Cybr-deficient 
mice with UBC-GFP mice for 8 generations. The colony was screened at each generation by PCR 
to detect  the homozygosity of the mutated form of Cybr, and by flow cytometry analysis to detect 
the homozygosity of GFP expression in the blood cells. 
 
C57BL/6 Rag2-/- γc-/- mice. These mice were purchased from Taconic (Laven, Denmark). The 
common gamma chain knockout (γc-/-) mouse lacks functional receptors for many cytokines 
including IL-2, IL-4, IL-7, IL-9, and IL-15. As a consequence, lymphocyte development is greatly 
compromised. The mouse lacks natural killer (NK) cells and produces only a small number of T and 
B cells. To eliminate the residual T and B cells, this mouse was crossed to the Rag2 (recombinase 
activating gene 2) deficient mouse. The double knockout lacks T cells and B cells, due to the 
inability to initiate V(D)J rearrangement, and lack NK cells. Double knockout mice were found to 
appear normal except for thymuses, spleens and lymph nodes, that were small and hypoplastic. No 
detectable alterations were observed in other tissues tested. In the Results section they are referred 
to as Rag2-/- γc-/- mice. 
 
2. Mouse DNA extraction  
Genomic DNA was obtained from mouse whole blood collected by retrorbital puncture under 
isofluorane/oxygen anesthesia and purified by using Puregene Blood Kit (Qiagen, Milan, Italy). 
After treatment with EDTA (pH 8, 0.5 M) as anticoagulant, erythrocytes were lysed using RBC 
(Red Blood Cells) lysis solution 1X (Qiagen). White blood cells (WBC) were lysed with an anionic 
detergent (Cell Lysis Solution, Qiagen), and RNA was removed by treatment with a RNase A 
solution (Qiagen). Other contaminants, such as proteins, were removed by salt precipitation (Protein 
Precipitation Solution, Qiagen). Finally, the genomic DNA was recovered by precipitation with 
isopropanol, washed with ethanol and resuspended in sterile water. The DNA was stored at -20°C. 
 
3. PCR for Cybr-deficient mouse screening   
Genomic DNA samples extracted from WBCs of Cybr-deficient/GFP mice were tested by PCR in 
order to detect the mutant form of Cybr gene. Cybr-deficient DNA was used as positive control. 
The following primers were used: 
A) 5’-GAGTATCAAACTCTATGTTCCGGCTG-3’ 
B)  5’-GGAATAAGGCTGGTAGTCAAAG-3’ 
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C) 5’-GAGAGGGGCGGATCAATTCATAACT-3’ 
PCR conditions were the followings: 
1) 96°C 2 min; 
2) 94°C 1 min; 
3) 53°C 1.5 min; 
4) 72°C 3 min; 
Steps from 2 to 4 were repeated for 40 cycles; 
5) 72°C 10 min; 
6) 4°C hold. 
The expected resulting fragments were 600 bp corresponding to the wild type gene, and 340 bp 
corresponding to the Cybr-KO gene. PCR-amplified DNA samples were then electrophoretically 
run on a 2% agarose gel.  
 
4. Preparation of blood samples for flow cytometric analysis of Cybr-
deficient/GFP mice 
Mouse blood samples were collected in a tube with EDTA to avoid blood coagulation. RBCs were 
lysed for 7 minutes at 37°C with 0.83% NH4Cl (Sigma, Milan, Italy) and then washed with PBS. 
This procedure was repeated twice. WBCs obtained were resuspended in 250 µl PBS and flow 
cytometry analysis was performed to detect GFP+ cells. 
 
5. Tumor cell lines 
MBL-2, a T cell leukemia cell line (H-2b) derived from a M-MuLV-infected B6 mouse, were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 2 mM L-glutamine, 
10 mM HEPES, 20 µM 2-mercaptoethanol, 150 U/ml of streptomycin, 200 U/ml of penicillin and 
10% of heat-inactivated fetal bovine serum (FBS). All reagents were purchased from GIBCO BRL 
(Monza, Italy).  
 
6. Virus preparation and M-MSV tumor induction  
The cell extracts containing defective M-MSV copelleted with its natural helper M-MuLV (M-
MSV/M-MuLV) were prepared from primary sarcomas induced by serial passages in 1-week-old 
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BALB/c mice, which had an in vitro M-MSV titer of 3 × 105 PFU/ml on 3T3/FL cells. M-MSV 
extract (100 µl) was injected intramuscularly in the thigh region of adult mice, which developed 
sarcomas at the site of injection that underwent spontaneous regression within 15-20 days. Tumor 
growth was monitored daily by caliper measurements starting 6 days after inoculation when 
sarcomas become apparent and until day 20 when tumors disappear.  
 
7. Histological analysis  
To study the infiltrating cell population in M-MSV-induced tumors of Cybr-KO and B6 mice, 
animals were sacrificed at different days. Tumors were excised, formalin-fixed (PFA 1%, Thermo 
Scientific, Milan, Italy) for 1 hour and then transferred in PBS 20% sucrose (Sigma) for the 
hematoxylin and eosin (H&E) staining. Alternatively, they were frozen in OCT (Bio-Optica, Milan, 
Italy) for the immunohistochemical (IHC) analyses. Thigh muscles from normal B6 and Cybr-KO 
mice were used as negative controls. The H&E and IHC stainings were performed in collaboration 
with the group of Professor P. Musiani, Department of Medicine and Aging Science, University of 
Chieti, Italy. For the IHC staining, the sections were incubated with the following primary 
antibodies: rat anti-mouse CD4 (clone H129.19), CD8α (clone 53-6.7), CD11b (clone M1/70), Ly-
6G and Ly-6C (clone RB6-8C5), CD45R/B220 (clone RA3-6B2) (all from BD Pharmingen, 
Buccinasco, Italy), CD68 (clone FA-11; Abcam, Cambridge, UK), FoxP3 (clone FJK-16s; 
eBioscience, Milan, Italy) mAbs; Armenian Hamster anti-mouse CD11c mAb (Clone HL3, BD 
Pharmingen). After incubation with the appropriate secondary antibodies, immunocomplexes were 
detected using Bajoran Purple Chromogen System (Biocare Medical, Concord CA, USA), and 
Vulcan Fast Red (Biocare Medical). 
 
8. TIL isolation 
Tumors excised at different time points after M-MSV injection were dissociated using a 
combination of mechanical tissue disruption and enzymatic digestion with a mixture of DNAse I 
(270 U/ml), Collagenase (200 U/ml) and Ialuronidase (35 U/ml) for 40 min at 37°C (all reagents 
were from Sigma). Cells suspensions were then washed twice and the tumor infiltrating 
lymphocytes (TIL) were analyzed at FACSCalibur (BD). 
 
9. Mixed Leukocyte Tumor Cell Cultures (MLTC) 
Mouse spleens were removed at different time points after M-MSV injection and MLTC cultures 
were set up by in vitro restimulation of 25 × 106 splenocytes with 106 syngeneic irradiated (60 Gy) 
MBL-2 cells. Cell cultures were maintained in DMEM, 10% FBS, in 25-cm2 tissue culture flasks 
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(Falcon, Becton Dickinson) for 5 days at 37°C, 5% CO2 and then tested for lytic activity in a 51Cr 
release assay. 
 
10. Peptides 
The Env189-196 (H-2Kb-restricted; SSWDFITV) peptide was obtained from Technogen (Naples, 
Italy). The Gag85-93 peptide (H-2Db-restricted; CCLCLTVFL) was modified by replacing  –SH 
groups with –OH groups, because it contains 3 cysteines forming disulfide bonds that avoid the 
correct biomonomer/tetramer folding. The modified peptide Abu-Abu-Leu-Abu-Leu-Thr-Val-Phe-
Leu (Gag/Abu, α-aminobutyric acid [140]) was thus synthesized at the Centro Ricerca 
Interdipartimentale Biotecnologie Innovative (CRIBI) of Padua University. All peptides were 
purified by high-performance liquid chromatography (HPLC) reaching a purity of >95%. 
Lyophilized peptides were finally dissolved in DMSO at 10 mM (Sigma) and stored at -80°C. 
 
11. MHC-biomonomer and MHC-tetramer preparation 
The synthesis of MHC-peptide tetrameric complexes is based on the use of prokaryotic expression 
systems for MHC class I heavy chain and β2-microglobulin. The MHC heavy chain (H-2Db for 
Gag/Abu peptide and H-2Kb for Env peptide) was modified by substitution of the transmembrane 
and cytosolic domains with a signal sequence containing a biotinylation site for the enzyme BirA. 
The MHC heavy chain, β2m and epitope peptide were subjected to a refolding in vitro in Tris-HCl 
pH 8, L-Arginin-HCl, NaEDTA, oxidized glutathione and reduced glutathione (Sigma). The 
complex was isolated through dialysis, concentrated and purified by HPLC to separate monomers 
from unconjugated components. Monomers were then enzymatically biotinylated by the enzyme 
BirA. The biomonomers obtained were purified and then quantified with a spectrophotometer. The 
tetramers were finally assembled with phycoerythrin (PE)-conjugated extravidin (Sigma) for the 
subsequent use of tetramers in flow cytometry analysis. The MHC-tetramers obtained were stored at 
4°C. The correct volume of extravidin-PE and hence the efficiency of tetramerization was verified 
by ELISA. Briefly, 96-well plates (Maxisorb, NUNC, Rochester, NY, USA) were coated overnight 
(ON) at room temperature (RT) with rabbit anti-human β2 microglobulin antibody (1:5000 in PBS 
1X; Genetex, Irvine CA, USA), that recognizes β2 microglobulin of free biomonomers. The coating 
was then removed and the assay buffer (AB: PBS 1X, 2% BSA, pH 7.4) was added for 1 hour at RT 
to saturate the aspecific sites. After three washes with wash buffer (WB: Tris HCl 50 mM, 0.2% 
Tween 20, pH 7.4), serial dilutions starting from 1 µg/ml of Gag or Env tetramers or the 
corresponding biomonomers were added for 1 hour at RT. The Gag and Env biomonomer solutions 
were used as positive controls. The plates were then washed three times with WB and Poly- 
42 
 
Horseradish Peroxidase-Streptavidin antibody (1:15000 in AB; Endogen, Rockford, IL, USA) was 
added for 1 hour at RT. After three washes with WB, OPD solution (o-Phenylenediamine 
dihydrochloride, Sigma) was added for 3-5 minutes for the detection of peroxidase activity. The 
reaction was finally stopped with HCl 3N and the absorbance was read at 490 nm in the ELISA 
plate reader (Victor X4 Multilabel Plate Reader; Perkin Elmer, Santa Clara, CA, USA). 
 
12. Cell staining and flow cytometry analysis 
To assess clonal dynamics ex vivo, fresh lymphocytes were isolated from lymph nodes, tumors and 
spleens at different time points, and labeled with Db-Gag(Abu) or Kb-Env tetramer-PE (5 µg/ml) for 
20 min at room temperature. Each sample was then stained with the APC-conjugated rat anti-mouse 
CD8a (clone 5H10; Invitrogen, San Giuliano Milanese, Italy) or the isotype control for 30 min at 
4°C and then analyzed on a FACSCalibur. Data collected were evaluated with FlowJo software 
(TreeStar Inc., Olten, Switzerland). Cells from non-injected mice were used as negative controls, 
while Gag- or Env-specific cytotoxic T lymphocytes clones, previously obtained in our laboratory, 
were used as positive controls [141]. 
 
13. Cytotoxicity assay  
The cytotoxic activity of MLTC was assessed in a 4h [51Cr]-release assay after 5 days of culture. 
Briefly, MBL-2 cells were labeled for 1 hour at 37°C with 100 µCi of Na251CrO4 (DuPont, Boston, 
MA, USA), washed twice and added to the effectors cells plated in serial dilutions, starting from an 
effector/target (E/T) ratio of 100:1. Triplicates for each assay condition were set in round-bottom 96 
well plates in a final volume of 200 µL/well. The supernatant was collected after 4 hours and 
radioactivity was assessed using a γ-counter (Cobra Gamma Counting System, Packard Instrument 
Company). The percentage of specific lysis was calculated as [(cpm experimental release − cpm 
spontaneous release)/ (cpm maximum release − cpm spontaneous release)] × 100. Where indicated, 
cytotoxic activity was expressed in terms of Lytic Unit (LU)30 or LU15 (number of effectors in 1 x 
106 of total effectors, which cause 30% or 15% of lysis). 
 
14. Adoptive Cell Therapy (ACT) 
Single-cell suspensions were obtained from spleens of UBC-GFP and Cybr-deficient/GFP donor 
mice. Naive T cells were isolated using Pan T cell isolation kit II (Miltenyi Biotec, Calderara di 
Reno, Bologna, Italy), according to the manufacturer instructions. Briefly, splenocytes were 
resuspended in staining buffer (PBS pH 7.2, 0.5% bovine serum albumin-BSA, and 2 mM EDTA) 
and incubated at 4°C for 10 min with the proper amount of Biotin-Antibody Cocktail. This cocktail 
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comprises biotin-conjugated monoclonal antibodies against CD11b, CD11c, CD19, CD45R (B220), 
CD49b (DX5), CD105, MHC class II, and Ter-119. Microbeads conjugated to an anti-biotin mouse 
mAb were then added for additional 15 min. After washing, purified naive T cells were obtained by 
magnetic negative separation using a LS column. The isolated populations were stained with APC-
conjugated rat anti-mouse CD8a (clone 5H10, Invitrogen), CD19 (PeCa1; Immunotools, Friesoythe, 
Germany), F4/80 (clone BM8; Biolegend, London UK), and PercP-conjugated rat anti-mouse  CD4 
(clone GK1.5; Biolegend), and Armenian Hamster anti-mouse CD3e (clone 145-2C11, BD 
Pharmingen), to assess their purity by flow cytometry analysis. A total of 10 x 106 naive T cells 
were then injected into the tail vein of recipient RAG2-/- γc-/- mice after M-MSV injection. Mice 
were daily monitored for tumor growth by caliper measurement. Moreover, at different time points 
and until day 29 after the M-MSV and T cell injection, blood was collected and analyzed by flow 
cytometry. WBC were stained with the Armenian Hamster anti-mouse CD3e (clone 145-2C11, BD 
Pharmingen) or the isotype control for 30 min at 4°C and then analyzed on a FACSCalibur. At day 
32, tumors, spleen and lymph nodes were collected and analyzed for the presence of GFP T cells. 
Each sample was labeled with Db-Gag(Abu) or Kb-Env tetramer and then stained with the APC-
conjugated rat anti-mouse CD8a (clone 5H10, Invitrogen) or the isotype control for 30 min at 4°C 
and then analyzed on a FACSCalibur. Data collected were evaluated with FlowJo software 
(TreeStar Inc.). 
 
15. Statistical analysis 
For the kinetics data, ANOVA for repeated measurements was performed to determine a significant 
difference between the tumor growth in control and Cybr-deficient groups. P< 0.05 (*) and P<0.01 
(**) were considered to be statistically significant. Statistical differences between mean values of 
lymphocytes numbers, CD8+, CD8+/Gag+ and CD8+/Env+ CTL expressions were calculated with 
the Student t test for independent samples. 
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RESULTS 
1. Assessment of growth kinetics of M-MSV/M-MuLV-induced sarcomas in wild 
type and Cybr-deficient mice  
To assess the potential role that Cybr could play in the immune response mediated by T 
lymphocytes, we took advantage of our knowledge of MSV mouse model, which had been 
previously characterized in depth in our laboratory. Briefly, the intramuscular injection of M-MSV 
causes sarcomas that develop at the inoculation site, after a short period of latency. Subsequently, 
tumors regress because of a strong immune reaction primarily mediated by CTL specific for viral 
antigens [141]. Thus, Cybr-deficient and wild type B6 mice were injected intramuscularly with the 
retroviral complex and the tumor growth was monitored up to day 20 after virus injection. The 
incidence of tumor development in Cybr-deficient mice appeared slightly higher (67 out of 76, 
88%) compared to wild-type mice (64 out of 86, 74%). Notably, Cybr-deficient mice developed 
larger sarcomas that additionally underwent regression with a slower kinetics in contrast to that 
observed in control mice (P < 0.001; Fig. 1). Furthermore, we noticed, that such difference was 
more evident from day 11 to day 15 after virus injection, which corresponds to the phase where the 
tumors reached the maximum size.   
 
 
Figure 1:  Analysis of M-MSV-induced tumor growth in Cybr-deficient mice. Cumulative kinetics of 
tumor growth in Cybr-knockout (filled circles) and wild type control littermates (open circles). Sixty-seven 
out of 76 (88%)  Cybr-deficient and 64 out of 86 (74%) wild-type mice developed sarcomas after the 
intramuscular injection of M-MSV. Tumor size (in millimeters) was monitored up to day 20. P < 0.001 
(ANOVA Repeated measures analysis of variance). 
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2. Histological and immunohistochemical analyses of Cybr-KO mouse tumors.  
Based on the information of tumor growth kinetics in Cybr-deficient and wild-type mice, we 
decided to study the immune cells infiltrating the tumor site at different days during cancer 
development and regression. Indeed, our purpose was to detect any possible difference in the cell 
types infiltrating tumors between Cybr-deficient and B6 mice, to gain insight about potential 
mechanisms involved. Thus, mice were injected with the retroviral complex and sacrificed at 
different time points. Tumors were then collected and evaluated by H&E staining and by 
immunohistochemistry. Representative images of tumor sections from day 9 to 15 of H&E staining 
are reported in Figure 2. 
We could not notice apparent differences in the overall amount of tumor cellular infiltrate between 
the two groups. In both of them, the infiltrate gradually increased from day 9 to day 13 to gradually 
decrease thereafter, as expected by the resolution of the inflammatory process. Conversely, the 
immunohistochemical analyses (Fig. 3) showed some differences in terms of the cellular types 
infiltrating the tumors. As it can be observed in representative tumor sections at day 12, the day of 
the maximal tumor growth, the rich inflammatory infiltrate appeared to be mainly constituted by 
cells of the myeloid lineage: neutrophils expressing Gr-1, macrophages expressing CD11b and, in a 
large percentage, also CD68. Only a few CD11c+ dendritic cells were present. No significant 
differences in myeloid infiltrate were evident between the two strains (Fig. 3A). However, the 
number of infiltrating T cells was quite different between the two groups. Indeed, both CD4+ and 
CD8+ cells were less represented in Cybr-KO compared to wild-type mice. Notably, no Fox-p3 
positive cells (regulatory T cells) were present and CD45R+ B cells were scarcely represented in 
either strain (Fig. 3B). 
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Figure 2:  Histological analyses of Cybr-KO and B6 mouse tumor sections. Representative images of 
tumor sections from day 9 to 15 in H&E staining (20X). 
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Figure 3: Immunohistochemical analyses of Cybr-KO and B6 mouse tumor sections. Analyses of A) 
myeloid and B) T cells markers. Representative images of tumor sections at day 12, the day of the maximal 
tumor growth, are reported. 
 
3. Evaluation of virus-specific CTL response in tumors, lymph nodes and spleens 
of M-MSV-injected wild-type and Cybr-deficient mice. 
To assess the immunological features that may be responsible of the different tumor growth kinetics 
between Cybr-deficient and wild-type mice, animals of both groups were injected with the retroviral 
complex and sacrificed at the peak of tumor growth (day 11, 12, 13 and 15 after virus injection). 
Subsequently, tumors, spleens and tumor-draining lymph nodes were collected, the leukocytes 
isolated and finally analyzed by flow cytometry in order to evaluate the amount and specificity of 
the CD8+ T cell populations directed to the Gag and Env viral antigens.  
For this purpose, we took advantage of the tetramer technology in use in our laboratory. The Gag- 
and Env-specific tetramers were produced from the corresponding biotinilated biomonomers by the 
addition of Extravidin-PE, and subsequently were purified by HPLC. The tetramerization was 
carried out with good efficiency, as assessed by ELISA (Fig. 4A). Indeed, the presence of free 
biomonomers was negligible in both tetramer preparations, since the absorbance values obtained 
were markedly lower than the corresponding unlinked biomonomers. Then, the capacity of 
tetramers to stain specific T cell clones isolated from splenocytes of tumor regressor mice [139], 
was tested by flow cytometry. Results clearly showed that both tetramers were capable to stain 
100% of cells with a relatively high intensity (Fig. 4B). 
Cybr-deficient and wild-type B6 tumors were collected and processed with a cocktail of enzymes 
that digest tissues to obtain tumor infiltrating leukocytes (TIL) in suspension. Leukocytes were 
counted and normalized with the tumor volumes (Fig. 5A). Although no apparent differences were 
noticed at day 11, at day 12, the day of the maximal tumor growth in both groups of animals, the 
number of TIL was clearly lower in Cybr-deficient mice than wild type B6 animals (P <0.01). 
Moreover, while the amount of TIL in B6 mice gradually decreased during the following days, the 
number of TIL in Cybr-deficient mice remained nearly constant and started to rise only by day 15. 
These data were further confirmed by flow cytometry analysis of the CD8+ T cell populations in 
TIL, which disclosed a three day delay in the increase of lymphocytes in Cybr-deficient mice 
compared to wild type animals (Fig. 5B). To evaluate the amount of CD8+ T cell populations 
specifically directed to the Gag and Env viral antigens, we subsequently stained the TIL with the 
specific tetramers. The results obtained are presented as number of lymphocytes positive for the 
specific tetramers (CD8+/Gag+ and CD8+/Env+) adjusted according to the tumor volume (Fig. 5C 
and D). Data confirmed the same trend observed previously, emphasizing the difference between B6 
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and Cybr-deficient lymphocytes especially at day 13, although they did not always reach statistical 
significance. In contrast, the number and the tetramer specificity of lymphocytes isolated from 
lymph nodes and spleens were not different between the two groups of mice (Fig. 6 and 7, 
respectively). Representative flow cytometry images of such experiments are presented in panel E 
and F of Figure 5, 6 and 7.  
 
 
 
Figure 4. Evaluation of Gag- and Env-specific tetramers. A) Tetramerization efficiency of Gag-specific 
(left panel) and Env-specific tetramers (right panel), as assessed by ELISA. The absorbance of different 
dilutions (starting from 1µg/ml) of the tetramer preparations (open circle) and the respective biomonomers 
(filled circles) were compared. B) Flow cytometry analysis was performed to evaluate the capacity of 
tetramers to stain Gag-specific (left panel) and Env-specific (right panel) T cell clones.  
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Figure 5. Analysis of leukocytes and specific CTL populations in tumors of Cybr-deficient and B6 mice 
at days 11-12-13-15 after M-MSV injection. A) Leukocytes numbers standardized with the correspondent 
tumor volume in Cybr-deficient and B6 mice. Figure shows mean + SD of 4 independent experiments (10-15 
mice/day for each strain). B) CD8+ T lymphocytes as analyzed by flow cytometry after correlation with 
leukocyte numbers shown in A. C) CD8+/Gag+ and D) CD8+/Env+ T lymphocyte analyzed by flow cytometry 
and correlated with leukocyte numbers shown in A. E, F) Representative images of flow cytometry analyses 
of CD8+/Gag+ (E) and CD8+/Env+ T cells population (F) in B6 and Cybr-deficient mice at day 13. * P<0.05 
and ** P<0.01 versus wild type, Student’s t-test for independent samples. 
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Figure 6. Analysis of leukocytes and specific CTL populations in lymph nodes of Cybr-deficient and B6 
mice at days 11-12-13-15 after M-MSV injection. A) Leukocytes numbers in lymph nodes of Cybr-
deficient and B6 mice. Figure shows mean + SD of 4 independent experiments (10-15 mice/day for each 
strain). B) CD8+ T lymphocytes as analyzed by flow cytometry after correlation with leukocyte numbers 
shown in A. C) CD8+/Gag+ and D) CD8+/Env+ T lymphocyte analyzed by flow cytometry and correlated 
with leukocyte numbers shown in A. E, F) Representative images of flow cytometry analyses of CD8+/Gag+ 
(E) and CD8+/Env+ T cells population (F)in B6 and Cybr-deficient mice at day 13. * P<0.05 and ** P<0.01 
versus wild type, Student’s t-test for independent samples. 
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Figure 7. Analysis of leukocytes and specific CTLs populations in spleens of Cybr-deficient and B6 
mice at days 11-12-13-15 after M-MSV injection. A) Leukocytes numbers in spleens of Cybr-deficient and 
B6 mice. Figure shows mean + SD of 4 independent experiments (10-15 mice/day for each strain). B) CD8+ 
T lymphocytes as analyzed by flow cytometry after correlation with leukocyte numbers shown in A. C) 
CD8+/Gag+ and D) CD8+/Env+ T lymphocyte analyzed by flow cytometry and correlated with the leukocyte 
numbers, shown in A. E, F) Representative images of flow cytometry analyses of CD8+/Gag+ (E) and 
CD8+/Env+ T cells population (F) in B6 and Cybr-deficient mice at day 13. * P<0.05 and ** P<0.01 versus 
wild type, Student’s t-test for independent samples. 
 
56 
 
4. Functional characterization of CTL. 
To functionally characterize and compare the CTL populations in Cybr-deficient and wild type 
mice, we analyzed the cytotoxic activity of MLTC set up from spleens of either strain. MLTC were 
obtained by co-culturing splenocytes collected at days 11, 13 and 15 after M-MSV injection with 
irradiated MBL-2 tumor cells expressing viral antigens. As shown in Figure 8A, Cybr-deficient 
CTLs displayed a significantly lower lytic activity than wild type CTLs at day 11 (P<0.05). The 
lytic activity difference between the two groups was observed also at days 13 and 15, although 
individual variability of cultures precluded the achievement of a statistical significance. By 
expressing the data in terms of LU30 (Fig. 8B), the differences between the lytic capacity of the two 
groups can be further better appreciated. At day 11, Cybr-deficient CTLs were confirmed to exert a 
significant lower cytotoxicity than effectors from wild type mice (P<0.05), while lytic function was 
recovered by days 13 and 15 and was similar to control CTLs.  
To verify whether the lower lytic activity displayed by Cybr-deficient CTLs at day 11 was simply 
due to a reduced number of Gag- and Env-specific T cells in culture, we analyzed the percentages 
of virus-specific T cells in MLTC from mutant and B6 mice by tetramer staining before the 
cytotoxic assay.  
Tetramer-specific CD8+ T cells turned out to be more represented in MLTC from B6 than Cybr-
deficient mice (day 13: 7.45 % vs 3.67% for B6 and Cybr-deficient cultures, respectively; day 15: 
31.8% vs 11.85% for B6 and Cybr-deficient cultures, respectively), an exception being represented 
by day 11 when they appeared to be comparable (9.7% vs 6.6% for B6 and Cybr-deficient cultures, 
respectively). Therefore, data expressed in terms of LU30 were corrected for the percentage of 
specific CTLs to obtain more accurate information about the specific lysis of MLTC. Hence, Cybr-
deficient specific CTLs disclosed a lower lytic activity only at day 11 (Fig. 8C), while they fully 
recovered and were even more cytotoxic than their wild type counterparts by day 15.  
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Figure 8. Analysis of lytic activity of Cybr-deficient and B6 CTL. A) Cytotoxic activity of Cybr-deficient 
and B6 MLTC, as assessed by standard 4h chromium release assay. MLTC were set up at days 11, 13, 15 
after M-MSV injection and each MLTC was obtained from a pool of 4-5 animals. Figure shows mean +/- SD 
of four independent experiments. B) Cytotoxic activity as in (A) is reported in terms of LU30. * refers to a 
statistically significant difference (P=0.018, Student’s t-test for independent samples). C) LU30  corrected for 
the percentage of CD8+/tetramer+ CTL populations, as obtained by flow cytometry analysis. Figure shows a 
representative experiment out of 4 carried out.   
 
 
 
 
58 
 
5. Assessment of lytic activity of Cybr-deficient and wild type CTLs from tumor 
regressor mice. 
To compare the lytic activity of memory T cells from wild type and Cybr-deficient mice,  
splenocytes were isolated at day 40 after M-MSV injection, when mice of both strains had 
completely regressed the tumors, and MLTC were set up to be subsequently tested in a standard 
chromium release assay. As reported in Figure 9A, 6 weeks after retroviral complex injection CTLs 
from both Cybr-deficient and wild-type mice exhibited a fully overlapping lytic activity. These 
results are even more evident when data are expressed in terms of LU15 (Figure 9B) and also 
confirmed by the correction  with the percentage of tetramer specific T cells (data not shown).  
 
 
 
Figure 9. Analysis of lytic activity of Cybr-deficient and wild type CTLs from tumor regressor mice. A) 
Cytotoxic activity of Cybr-deficient and B6 MLTC as assessed by standard 4h chromium release assay. 
MLTC were set up from pools of 5 animals each 40 days after M-MSV injection. Figure shows mean +/- SD 
of four independent experiments. B) Cytotoxic activity as in A) was expressed in terms of LU15.  
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6. Generation of Cybr knockout/GFP mice. 
With the aim to develop a tool to track Cybr-deficient T cells in in vivo models after adoptive 
transfer experiments, we generated a Cybr-deficient/GFP mouse strain. Having in our animal 
facility the UBC-GFP mice, the Cybr-deficient/GFP mouse strain was obtained by crossing the 
eGFP-transgenic mice with Cybr-KO animals for at least 8 generations. The colony obtained was 
screened at each generation by PCR to detect the homozygosity of Cybr mutant gene (Fig. 10A)  
and by flow cytometry analysis to detect the GFP expression (Fig. 10B). Because of a dose-effect 
mechanism, the expression of GFP in homozygous and in hemizygous mice is characterized by a 
different intensity, thus allowing to clearly distinguish the two conditions.  
 
 
 
Figure 10. Analysis of Cybr-Knockout/GFP mice. A) Expression of Cybr mutant gene in genomic DNA 
extracted from peripheral blood of Cybr-KO/GFP mice. The samples were loaded for electrophoresis in the 
following order: lines 1 to 4, sample of  homozygous mutant gene of Cybr-KO/GFP mice; line 5 
homozygous mutant gene of Cybr-KO mice control; line 6, heterozygous gene of Cybr-KO/GFP mice; line 
7, wild type gene of B6 mouse; line 8, water; line 9, base pairs ladder (bp). B) GFP expression, as assessed 
by flow cytometry analysis, in leukocytes obtained from peripheral blood of Cybr-KO/GFP mice. Blood 
from wild-type B6 mice (red peak) was used as negative control, while blood from UBC-GFP and from 
UBC-GFP x Cybr-KO F1 mice were used as homozygous (blue peak) and heterozygous (green peak) GFP 
expression controls, respectively.  
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7. Adoptive transfer of naive GFP-T cells from Cybr-deficient and B6 mice into 
Rag2-/- γc-/- animals. 
To understand the mechanistic role of Cybr in the priming or effector phases of the immune 
response, further experiments were performed using the Rag2 -/- γc -/- mouse model, which lacks T, 
B and NK cells  [142],[143]. First, M-MSV was injected into Rag2-/- γc-/- and the tumor growth 
was monitored (Fig. 11A). As expected because of the absence of T cells in Rag2-/- γc-/-, the 
tumors continued to grow without undergoing regression, as compared to the wild type mice. Then, 
ACT experiments were set up by transferring 10 x 106 purified naive T cells (96% CD3, 34% 
CD3+/CD8+, 62% CD3+/CD4+, 0,15% CD19+, 0,35% F480+) obtained from spleens of B6/GFP or 
Cybr-deficient/GFP mice, into M-MSV-injected Rag2-/- γc-/-, and tumor size was monitored daily 
by caliper measurement (Fig. 11B). Untreated M-MSV-inoculated RAG2-/- γc-/- were used as 
controls. Until day 10, mice treated with purified T cells from either strains did not developed 
tumors, which were conversely evident in RAG2-/- γc-/- control mice. From day 12 to day 18, 
RAG2-/- γc-/- mice receiving Cybr-deficient/GFP T cells presented neoplastic masses that were 
larger than those appearing in animals treated with B6/GFP T cells;  nonetheless, tumors in mice 
undergoing ACT with T cells from either mouse strains were smaller than those of untreated 
RAG2-/- γc-/- mice, although the observed differences did not reach statistical significance. After 
the day 18, tumors continued to growth in all groups, suggesting that transferred naive T cells were 
not able to mount a fully effective immune response.  
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Fig.11. Analysis of M-MSV-induced tumor growth in Rag2-/- γc-/- mice. A) Kinetics of tumor growth in 
Rag2 -/- γc-/- mice injected with M-MSV (filled circles) is reported in comparison to that of wild-type 
control mice (open circles). All mice developed sarcomas, but Rag2 -/- γc-/- mice did not regress M-MSV-
induced tumors. This preliminary experiment was set up with 5 animals for each group. B) Kinetics of tumor 
growth in Rag2 -/- γc-/- mice injected with M-MSV and receiving Cybr-deficient/GFP (filled circles) or  
B6/GFP T cells (open circles). For each group, 6 animals were injected while untreated Rag2 -/- γc-/- mice 
inoculated with M-MSV were used as control. 
 
Moreover, blood samples were collected at different time points after ACT and the presence and 
amount of transferred GFP T cells were evaluated. In the peripheral circulation, the leukocyte 
counts were similar between the two groups (Fig. 12A). Blood specimens were further analyzed for 
the percentage of CD3+/GFP+ cells and a similar kinetic trend was observed, even though B6/GFP T 
cell-injected mice displayed higher percentages of GFP+ T cells in the circulation (Fig. 12B). By 
expressing the obtained data in terms of fold-increase, with the post-injection value of both groups 
of mice considered as baseline (Fig. 12C), we found that the percentage of circulating Cybr-
deficient T lymphocytes was significantly lower than that of wild type T cells only at day 7 
(P=0.041). Moreover, based on the CD3+/GFP+ cell percentages and the number of counted 
leukocytes, we could extrapolate the absolute number of transferred T cells in the peripheral blood 
(Fig. 12D). Again, by expressing the results as fold-increase (Fig. 12E) it was confirmed that a 
significant difference (P<0.0001) was present only at day 7.  
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Figure 12. Assessment of Cybr-deficient/GFP and B6/GFP T cells adoptively transferred in Rag2-/- γc-
/- mice. A) Number of peripheral blood leukocytes in Rag2 -/- γc-/- mice injected with M-MSV and 
receiving Cybr-deficient/GFP (filled circles) or B6/GFP T cells (open circles). B) Percentages (mean +/- SD) 
of CD3+/GFP+ T cells in peripheral blood at different time points after virus injection and ACT. C) Fold-
increase of percentage data. * P=0.041, Student’s t-test for independent samples. D) Number of CD3+/GFP+ 
T cells in peripheral blood calculated on the basis of leukocyte counts (A) and CD3+/GFP+ percentages (B). 
E) Fold-increase of CD3+/GFP+ T cells. ** P<0.0001, Student’s t-test for independent samples. 
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Finally, mice were sacrificed at day 32 and leukocytes were isolated from the tumors, spleens and 
lymph nodes. Although no difference was found in the number of leukocytes isolated from tumors 
of either group of animals (data not shown), no CD8+/GFP+ T cells could be recovered from these 
samples. Tumor-draining lymph nodes were hypoplastic and were detected only in few animals, 
thus precluding a flow cytometry analysis of the CD8+/GFP+ populations. Moreover, differences 
were not found in the number of leukocytes isolated from spleens of Rag2-/- γc-/- mice injected 
with B6/GFP or Cybr-deficient/GFP T cells (Fig. 13A). The CD8+/GFP+ component was also 
similar in both groups (Fig. 13B and 13C), but Gag- or Env-specific CTLs could not be detected.  
 
 
Figure 13. Spleen cell analysis at day 32 after adoptive transfer. A) Figure shows the number of 
leukocytes found in spleens of M-MSV-injected Rag2-/- γc-/- mice and inoculated with Cybr-deficient/GFP 
or B6/GFP T cells. B) and C) show the percentages and numbers of CD8+/GFP+ T cells, respectively. Data 
are the means + SD of 6 mice receiving B6/GFP or Cybr-deficient/GFP T cells. 
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DISCUSSION 
 
Cybr is a scaffold protein highly expressed in the hematopoietic/immune system. Its interaction 
with members of the cytohesin family [95],[101] is interesting because of its ability to control ARF 
function and to regulate LFA-1-mediated cell adhesion in T cells [96],[100]. Specifically, Cybr 
diminishes stimulated adhesion of LFA-1 to ICAM-1 [96], and also regulates T cell attachment and 
detachment from contact zones to DCs [100],[87]. These findings place Cybr in a crucial position to 
control cell adhesion and trafficking of the immune system cells; however, the knowledge about 
this protein is still limited and mainly relies on in vitro studies.  
First insights from the two available Cybr-deficient mouse strains [104],[103] showed that the 
development of the immune system is only marginally affected by the targeted deletion of Cybr, 
and that these mice display a reduced or delayed capacity to respond in stress conditions to different 
stimuli, namely Th1 polarized settings [104]. 
The purpose of this project was therefore to investigate the biological relevance of Cybr in vivo in a 
model of viral induced tumorigenesis, namely the M-MSV mouse model [144], taking advantage of 
the Cybr-deficient mouse strain described by Coppola and colleagues [104]. The intramuscular 
inoculation of the M-MSV retroviral complex in immunocompetent mice gives rise to sarcomas that 
rapidly undergo spontaneous regression, due to a strong immune reaction mainly mediated by CTL 
specific for viral antigens, in particular Gag and Env antigenic peptides [141]. 
In this setting, we found that Cybr-deficient mice developed larger sarcomas that additionally 
regressed with a slower kinetics in comparison to control mice. To characterize which subset of 
immune cells was affected in Cybr deficiency, we studied the immune cells infiltrating the tumors 
by H&E staining and by immunohistochemistry. As expected [144], tumors were characterized by a 
rich infiltrate mainly constituted by cells of the myeloid lineage (neutrophils, macrophages and 
CD11c+ dendritic cells), without apparent differences between wild type and Cybr-deficient mice. 
However, with regard to TIL, Cybr-KO mice were characterized by a reduced number of both CD4+ 
and CD8+ T cells compared to wild type mice. The relevant presence of CD4+ Fox-p3 negative T 
cells (comparable to that of CD8+ T cells in both strains) underlines the important role of this subset 
in tumor immune response. Indeed, as previously reported [145], mice injected with depleting anti-
CD4 antibody did not generate virus-specific cytotoxic T lymphocytes and ultimately died with 
progressing sarcomas at the inoculation site. Based on the increasing importance as effector cells in 
tumor immunity and the impact of Cybr on CD4+ T cell function [146], the role of this subset in our 
model needs further investigation. However, in this work we mainly focused our attention primarily 
on CD8+ T cells. Specifically, we characterized the CTL clonal dynamics in tumor, lymph nodes 
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and spleen in correspondence of maximal tumor growth (day 11, 12, 13 and 15 after virus 
injection), by means of flow cytometry analysis and tetramer staining. 
In line with immunohistochemistry analysis, we found an overall reduction in the number of 
lymphocytes infiltrating the tumor, as well as in the number of virus-specific CTLs in Cybr-
deficient mice compared to the wild type mice. This difference was more evident at day 12 and 13, 
while at day 15 the number of TIL in Cybr-KO mice steadily rised and was comparable to values 
found in wild type mice. The delay in tumor cell infiltration is consistent with the hypothesis that 
Cybr-deficiency negatively affects leukocyte trafficking, especially in response to proinflammatory 
cytokines in stress conditions, as it happens in the response to the M-MSV-induced tumors. 
Moreover, in line with results of Coppola and colleagues [104], we found no differences in number 
and specificity of splenocytes in the  two mouse strains. With regard to lymphocyte numbers in 
tumor-draining lymph nodes, a trend similar to that reported by Coppola and colleagues [104] was 
also observed, although our data did not reach statistical significance. 
Additionally, we observed a delayed onset of the lytic activity in the Cybr-deficient specific CD8+ T 
cell population. Indeed, Cybr-deficient CTLs displayed a lower cytotoxicity than wild type mice at 
day 11, while at day 15 they displayed a lytic activity comparable to that exerted by wild type CTLs 
at day 12. Thus, it appears that Cybr deficiency does not produce a strong immunodepression but is 
responsible of a mild immunodeficient phenotype, characterized only by a delay in the expansion of 
T lymphocytes in the tumor and also in the onset of their lytic activity, both defects being recovered 
in few days, an overall phenomenon that could be likely ascribed to the regulation of LFA-1 exerted 
by Cybr. Indeed, it was previously reported that the injection of anti-LFA-1 antibody enhanced 
tumor growth, delayed regression and also negatively impacted on the cytotoxic activity 
[147],[148]. Nonetheless, the involvement of Cybr in the events downstream the TCR engagement 
(namely, MAPK, JNK, p38, AP-1 and NFAT activation) [97] cannot be excluded in the delayed 
onset of lytic activity in Cybr-deficient CD8+ T cells, and require further studies. 
Interestingly, the increased tumor growth in Cybr-deficient mice appears to strictly correlate with 
the temporary impairment of CTLs, both in terms of overall number and lytic activity respect to 
wild type CTLs; as soon as these defects were recovered, tumors finally regressed in both groups of 
mice. Indeed, at day 40 after retroviral complex injection, Cybr-deficient and wild type CTLs from 
tumor regressor mice, displayed a fully overlapping lytic activity. These data suggest that naive T 
cell activation and the expansion of primed T cells are primarily affected by the influence of Cybr’s 
regulatory activity. 
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Collectively, our data indicate that Cybr deficiency has a significant impact on antigen-specific 
immune response, but it is still not clear whether Cybr mostly impacts on priming and/or cell 
adhesion, or in trafficking and migration of cells in the immune system.  
In an attempt to answer the biological question whether Cybr deficiency plays a major role in the 
priming or in the effector phase of the T cell cytotoxic response, we set up a series of experiments 
of adoptive cell therapy in Rag2-/- γc-/- mice with a H-2b background; because of the lack of T, B 
and NK cells, in this immunodeficient strain the M-MSV injection leads to the development of 
sarcomas that do not spontaneously regress. Moreover, we took also advantage of a new mouse 
strain (Cybr-KO/GFP) produced in our laboratory by breeding Cybr-deficient mice with GFP-
transgenic B6 animals.  
Adoptive transfer of purified naive T cells from Cybr-KO/GFP or B6/GFP animals in M-MSV-
injected Rag2-/- γc-/- mice allowed to focus on the study of the T cell compartment. In particular, 
we investigated the effects of Cybr deletion on CTL priming on the T cell side, since dendritic cells 
of recipient mice carry a wild type form of this protein. Except for a delay in the onset of the tumor 
in mice injected with isolated B6/GFP T cells, no significant differences were found in the kinetics 
of sarcomas development in all groups of mice. Despite the fact that transferred T cells from both 
animal strains expanded in the host, as assessed by flow cytometry analysis of PBMC, tumors 
continued to growth without undergoing regression. This suggested that wild type and Cybr-
deficient transferred T cells were not able to mount a fully effective immune response. We inferred 
that the Rag2-/- γc-/- mouse did not represent an optimal model for our purposes. Likely, the 
physical structure of spleen and lymph nodes, found to be hypoplastic, precluded per se an efficient 
recruitment and hence an efficient priming of naive T cells. Therefore, ongoing experiments will 
involve different animal models. In this regard, reconstitution of nu/nu athymic B6 mice with T 
cell-depleted bone marrow from either B6 or Cybr-KO mice, followed by adoptive transfer of naive 
or memory T cells from Cybr-KO/GFP or B6/GFP animals, will provide the appropriate 
experimental set up to dissect the role of Cybr in the APC or T cell compartments. In particular, by 
transferring memory T cells from Cybr–KO/GFP or B6/GFP animals we will be able to potentially 
rule out a pure role in recirculation and homing to the tumor site, thus highlighting the impact that 
Cybr may have during the priming phases of immune response.  
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ABBREVIATIONS 
 
Ab: antibody 
ADP: adenosine diphosphate 
AFP: α-fetoprotein  
Ag: antigen 
AP-1: activator protein 1 
APC: antigen presenting cells 
ARF: ADP-ribosylation factor 
ARNO: ARF nucleotide binding site opener 
BCR: B cell receptor 
CALLA: common acute lymphoblastic leukemia antigen 
CASP: cytohesin-associated scaffolding protein 
CD: clusters of differentiation 
CEA: carcinoembryonic antigen 
cSMAC: central supramolecular activation complex 
CT Ag: cancer/testis antigens 
CTL: cytotoxic T lymphocytes 
Cybr: Cytohesin binder and regulator 
CYTIP: cytohesin interacting protein  
DC: dendritic cells 
dSMAC: distal supramolecular activation complex 
EBV: Epstein-Barr Virus 
EGF: epidermal growth factor 
Fas-L: Fas ligand 
FcγR: fragment crystallizable γ receptor 
FoxP3: forkhead box protein 3 
gp100: protein 
GRASP: GRP1-associated scaffolding protein 
GTP: guanosine triphosphate  
HBV: Hepatitis B Virus 
HCV: Hepatitis C Virus 
Her2/Neu: human epidermal growth factor receptor 2 
HLA: human leukocyte antigen 
HPV: Human Papilloma Virus 
HTLV-1: Human T-lymphotropic type I Virus 
ICAM-1: intercellular adhesion molecule 
IFNR: IFN receptor 
IgSF: immunoglobulin superfamily 
IL: interleukin  
INF-γ: interferon-γ  
ITAM: immunoreceptor tyrosine-based activation motifs  
JNK: c-Jun N-terminal kinase 
KLRG1: killer cell lectin-like receptor subfamily G member 1 
KO: knock-out 
KSHV: Kaposi’s Sarcoma Herpes Virus 
Lck: lymphocyte specific protein tyrosine kinase 
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LDA: limiting dilution analysis 
LFA-1: leucocyte function associated antigen 1 
LMP: large multifunctional protease 
MAPK: mitogen-activated protein kinase 
MART-1/MELAN-A: melanoma antigen recognized by T cells 
MDSC: myeloid-derived suppressors cells 
MHC: major histocompatibility complex 
M-MSV: Moloney murine sarcoma virus 
M-MuLV: Moloney murine leukemia virus 
MTOC: microtubule-organizing center 
NFAT: nuclear factor of activated T cell  
NK cells: natural killer cells 
NKT: natural killer T cells 
PAMPs: pathogen-associate molecular patterns 
PHA: phytohemagglutinin 
PK-C: protein kinase  
PKCθ: protein kinase C theta  
PLC-γ: phospholipase C gamma 
PMA: phorbol-12-myristate-13-acetate  
PMN: polymorphonuclear cells 
PRR: pattern recognition receptor  
PSA: prostate-specific antigen 
PSCDBP: pleckstrin homology Sec7 and coiled coil domains binding protein 
pSMAC: peripheral supramolecular activation complex 
SNX27: sorting nexin 27 
TAA: Tumor-Associated Antigens 
Tap: transporter associated with antigen processing 
TCM cells: central memory T cells 
TCR: T cell receptor 
TEM: effector memory T cells 
TGF-β: tumor growth factor-β  
TIL: tumor infiltrating leukocytes 
TIL: tumor infiltrating leukocytes 
TN cells: naive T cells  
TNFR: tumor necrosis factor receptor 
TNF-α: tumor necrosis factor-α 
TSA: Tumor-Specific Antigens 
TSCM cells: stem cell memory T cells 
VLA-4: very late antigen-4  
ZAP-70: zeta-chain-associated protein kinase 70 
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